

Approved



Zambia
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,585,905		1,585,905	326,987	1,912,892
USAID		211,486,998		211,486,998	10,143,837	221,630,835
DOD		13,389,730		13,389,730	3,690,000	17,079,730
PC		4,399,499		4,399,499	217,131	4,616,630
HHS/CDC	2,412,531	105,854,920		108,267,451	2,678,093	110,945,544
HHS/HRSA		3,200,000		3,200,000	0	3,200,000
State/AF		534,000		534,000	0	534,000
Total	2,412,531	340,451,052	0	342,863,583	17,056,048	359,919,631

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		1,512,723	5,597,452				4,717,324	0	11,827,499
HBHC		809,831	7,035,313		52,563		13,635,175	0	21,532,882
HKID		1,006,940	250,000			150,000	20,996,904	0	22,403,844
HLAB		985,211	4,414,292	1,000,000			4,338,411	0	10,737,914
HMBL			0					0	0
HMIN			0					0	0
HTXD			0				46,163,068	0	46,163,068
HTXS		4,985,803	39,132,437	200,000			61,378,507	0	105,696,747
HVAB			806,781		63,030	0	1,199,166	0	2,068,977

Approved



HVCT		709,831	5,440,908			0	11,736,945	0	17,887,684
HVMS	1,480,413	334,678	6,049,166		4,092,447		6,414,574	0	18,371,278
HVOP		412,723	3,635,782		191,459	150,000	9,320,235	0	13,710,199
HVSI	105,492	650,058	9,968,659				3,970,940	0	14,695,149
HVTB		414,457	7,459,910				3,957,565	0	11,831,932
IDUP			0					0	0
MTCT		26,024	8,823,664	500,000			7,602,724	0	16,952,412
OHSS		796,289	3,985,695	1,500,000		234,000	4,488,006	0	11,003,990
PDCS		87,518	2,059,205				4,430,616	0	6,577,339
PDTX		657,644	3,608,187				7,136,838	0	11,402,669
	1,585,905	13,389,730	108,267,451	3,200,000	4,399,499	534,000	211,486,998	0	342,863,583



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	21,283,012	0
HKID	22,078,397	0
HVTB	11,631,803	0
PDCS	6,366,541	0
Total Technical Area Planned Funding:	61,359,753	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	9,990,784	0
HVSI	10,897,265	0
OHSS	9,670,893	0
Total Technical Area Planned Funding:	30,558,942	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	11,564,551	0
HMBL	0	
HMIN	0	0
HVAB	1,912,891	0
HVCT	17,532,038	0
HVOP	13,457,114	0
IDUP	0	0
MTCT	16,506,708	0

Approved



Total Technical Area Planned Funding:	60,973,302	0
--	-------------------	----------

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	46,081,272	0
HTXS	105,106,809	0
PDTX	11,179,716	0
Total Technical Area Planned Funding:	162,367,797	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	573,784
	Number of new ANC and L&D clients	603,257
	By: Known positives at entry	46,631
	By: Number of new positives identified	44,564
	Sum of Positives Status disaggregates	91,195
	Required only for DREAMS Countries - By Number of new positives: <15	162
	Required only for DREAMS Countries - By Number of new positives: 15-19	1,412
	Required only for DREAMS Countries - By Number of new positives: 20-24	4,420
	Required only for DREAMS Countries - By Number of known positives: <15	96
	Required only for DREAMS Countries - By Number of known	1,686



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	5,080
	Required only for DREAMS Countries - Denominator: <15	3,775
	Required only for DREAMS Countries - Denominator: <15-19	42,502
	Required only for DREAMS Countries - Denominator: 20-24	93,898
	Required only for DREAMS Countries - Denominator: 25-49	199,052
	Required only for DREAMS Countries - Denominator: 50+	1,533
	Required only for DREAMS Countries - By Number of known positives: 25-49	18,011
	Required only for DREAMS Countries - By Number of known positives: 50+	79
	Required only for DREAMS Countries - By Number of new positives: 25-49	11,241
	Required only for DREAMS Countries - By Number of new positives: 50+	103
	By Age (DREAMS SNU's ONLY): <15	2,916
	By Age (DREAMS SNU's ONLY): 15-19	40,754
	By Age (DREAMS SNU's ONLY): 20-24	89,801
	By Age (DREAMS SNU's ONLY): 25-49	188,714



	By Age (DREAMS SNU's ONLY): 50+	1,346
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,791
	Number of new ANC and L&D clients	46,120
	By: Known positives at entry	3,864
	By: Number of new positives identified	2,580
	Sum of Positives Status disaggregates	6,444
	Required only for DREAMS countries - By known positives: <15	5
	Required only for DREAMS countries - By known positives: 15-19	38
	Required only for DREAMS countries - By known positives: 20-24	442
	Required only for DREAMS countries - By new positives: <15	12
	Required only for DREAMS countries - By new positives: 15-19	56
	Required only for DREAMS countries - By new positives: 20-24	492
	Required only for DREAMS countries - Denominator: <15	350



	Required only for DREAMS countries - Denominator: 15-19	729
	Required only for DREAMS countries - Denominator: 20-24	9,386
	Required only for DREAMS countries - Denominator: 25-49	27,718
	Required only for DREAMS countries - Denominator: 50+	2
	Required only for DREAMS countries - By known positives: 25-49	1,577
	Required only for DREAMS countries - By known positives: 50+	0
	Required only for DREAMS countries - By new positives: 25-49	1,362
	Required only for DREAMS countries - By new positives: 50+	0
	By Age (DREAMS SNUs ONLY): <15	350
	By Age (DREAMS SNUs ONLY): 15-19	724
	By Age (DREAMS SNUs ONLY): 20-24	9,385
	By Age (DREAMS SNUs ONLY): 25-49	27,723
	By Age (DREAMS SNUs ONLY): 50+	3
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	573,784
	New on ART	33,394
	Already on ART at beginning of current pregnancy	32,675
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	45,791
	New on ART	1,530
	Already on ART at beginning of current pregnancy	1,844
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	271,260
	By Age: 0-60 days	2,864
	By Age: 2 months - 9 years	44
	By Age: 10-14	62,913
	By Age: 15-19	64,535
	By Age: 20-24	58,005
	By Age: 25-29	55,060
	By Age: 30-49	20,245
	By Age: 50+	4,680



	Sum of age disaggregates (Prior to FY15)	190,133
	Sum of age disaggregates (FY15-Current)	265,438
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	267,921
	By circumcision technique: Device-based VMMC	653
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population	1,824,894



	who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
	Total number of people in the target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	



	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	191,729
	Aggregated Age/sex: 15+ Male	658,920
	Aggregated Age/sex: <15 Female	193,225
	Aggregated Age/sex: 15+ Female	781,020
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	72,829
	Total number of people in the target population	310,681
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	3,621
	Aggregated Age/sex: 15+ Male	31,797
	Aggregated Age/sex: <15 Female	4,376



	Aggregated Age/sex: 15+ Female	41,352
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,923
	Total estimated number of key population in the catchment area	14,545
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	374
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	0



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	27
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,912
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	322
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in	384



	prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	300
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	400
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	45
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	13,094
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	322



	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	384
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
KP_PREV_TA	KP_PREV_TA Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (TA-only)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
	Total estimated number of key population in the catchment area	



	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated	



	number of key population in the catchment area)	
	By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men and are sex	



	workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known positive	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	



	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,072,450
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	15,034
	Age/sex: 15-19 Male	26,954
	Age/sex: 20-24 Male	40,093
	Age/sex: 25-49 Male	104,473
	Age/sex: 50+ Male	15,667
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	16,106
	Age/sex: 15-19 Female	32,765
	Age/sex: 20-24 Female	55,333
	Age/sex: 25-49 Female	127,235
	Age/sex: 50+ Female	17,314
	Test Result by Age and Sex: Positive: 10-14 Male	1,858
	Test Result by Age and Sex: Positive: 15-19 Male	2,181
	Test Result by Age and Sex: Positive: 20-24 Male	3,888
	Test Result by Age and Sex: Positive: 25-49 Male	11,525
	Test Result by Age and Sex: Positive: 50+ Male	1,723
Test Result by Age and Sex: Positive: 10-14 Female	1,998	



	Test Result by Age and Sex: Positive: 15-19 Female	2,955
	Test Result by Age and Sex: Positive: 20-24 Female	5,429
	Test Result by Age and Sex: Positive: 25-49 Female	14,572
	Test Result by Age and Sex: Positive: 50+ Female	1,942
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	103,948
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	371,970
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15	105,509



	Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	486,283
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	9,345
	Test Result by Aggregated Age and Sex: Positive 15+ Male	37,332
	Test Result by Aggregated Age and Sex: Positive <15 Female	9,642
	Test Result by Aggregated Age and Sex: Positive 15+ Female	48,048
	Test Result by Age: Positive: <1	748
	Test Result by Age: Positive: 1-9	4,368
	Age/sex: <1	12,442
	Age/sex: 1-9	33,859
	Service Delivery Point (Community): Index testing	7,196
	Service Delivery Point (Community): Homebased testing	12,071
	Service Delivery Point (Community): Mobile testing	10,195
	Service Delivery Point (Community): Other	15,486
	Service Delivery Point (Community) by Age: <15 index testing	



	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	79,150
	Service Delivery Point (Facility): Outpatient	160,246
	Service Delivery Point (Facility): Pediatric	45,205
	Service Delivery Point (Facility): Malnutrition facilities	4,614
	Service Delivery Point (Facility): Other PITC	117,404
	Service Delivery Point (Facility): VCT	388,654
	Service Delivery Point (Facility): VMMC	66,073
	Service Delivery Point (Facility): PMTCT	104,217
	Service Delivery Point (Facility): TB Clinics	9,388
	Service Delivery Point (Facility): Index testing	48,184



	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	



	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	94,474
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	2,123
	Age/sex: 15-19 Male	3,757
	Age/sex: 20-24 Male	7,065
	Age/sex: 25-49 Male	14,601
	Age/sex: 50+ Male	1,892
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	3,019
	Age/sex: 15-19 Female	5,201
	Age/sex: 20-24 Female	8,373
	Age/sex: 25-49 Female	18,605
	Age/sex: 50+ Female	2,730
	Test Result by Age and Sex: Positive: 10-14 Male	152
	Test Result by Age and Sex: Positive: 15-19 Male	394
	Test Result by Age and Sex: Positive: 20-24 Male	709
	Test Result by Age and Sex: Positive: 25-49 Male	1,553
	Test Result by Age and Sex: Positive: 50+ Male	200
Test Result by Age and Sex:	216	



	Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	537
	Test Result by Age and Sex: Positive: 20-24 Female	868
	Test Result by Age and Sex: Positive: 25-49 Female	2,051
	Test Result by Age and Sex: Positive: 50+ Female	303
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,857
	Aggregated Age/sex - USE WITH	36,557



HQ PERMISSION ONLY: 15+ Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,139
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	47,544
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	341
Test Result by Aggregated Age and Sex: Positive 15+ Male	4,635
Test Result by Aggregated Age and Sex: Positive <15 Female	450
Test Result by Aggregated Age and Sex: Positive 15+ Female	7,020
Test Result by Age: Positive: <1	51
Test Result by Age: Positive: 1-9	108
Age/sex: <1	780
Age/sex: 1-9	2,554
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	
Service Delivery Point (Community): Mobile testing	
Service Delivery Point	



	(Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	1,229
	Service Delivery Point (Facility): Outpatient	8,092
	Service Delivery Point (Facility): Pediatric	1,457
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	7,397
	Service Delivery Point (Facility): VCT	58,884
	Service Delivery Point (Facility): VMMC	500
	Service Delivery Point (Facility): PMTCT	19,760
	Service Delivery Point (Facility): TB	1,730



	Clinics	
	Service Delivery Point (Facility): Index testing	5,217
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	29,689
	Total number of registered new and relapsed TB cases, during the reporting period.	27,958
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered	



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	989
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15,283
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	798
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,656
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the	



	reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,307



	Total number of registered new and relapsed TB cases, during the reporting period.	2,307
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	110
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,054
	Aggregated Age/Sex: Female <15	121



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,022
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	29,669
	Age/Sex: <10 Male	1,162
	Age/Sex: 10-14 Male	772
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	965
	Age/Sex: 25-49 Male	2,069
	Age/Sex: 50+ Male	691
	Age/Sex: <10 Female	1,848
	Age/Sex: 10-14 Female	2,232
	Age/Sex: 15-17 Female	



	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	3,333
	Age/Sex: 25-49 Female	7,208
	Age/Sex: 50+ Female	1,646
	Sum of Age/Sex Disaggregates	6,014
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20,944
	By type of service: Sexual Violence (Post-Rape Care)	6,725
	By PEP service provision (related to sexual violence services provided)	1,288
	Age/Sex: 15-19 Female	4,648
	Age/Sex: 15-19 male	1,096
GEND_GBV_TA	Number of people receiving post-GBV care	225
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	185
	By type of service: Sexual Violence (Post-Rape Care)	40



	By PEP service provision (related to sexual violence services provided)	40
	Age/Sex: 15-19 Female	
	Age/Sex: 15-19 Male	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	473,637
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	39,911
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	40,468
	Sum of Age/Sex disaggregates	80,379
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	20,169
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	17,418
	Required only for DREAMS countries - By service, age and sex: Education Support Female	1,184



	18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	17,302
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	12,509
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	752
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	839
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	19,762
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	8,685
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	2,994



	Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	6,354
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	839
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	19,487
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	8,577
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	2,889
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	6,353
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	1,110
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	31,271
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	17,547



	15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	881
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	1,110
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	31,002
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	17,219
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	564
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	1,081
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	29,798
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	16,552



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,134
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	1,081
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	29,619
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	16,335
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	1,244
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	0
	Required only for DREAMS	0



	countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	0
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	11,176
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	23,865
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs	31,756



	Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	30,904
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	0
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	665
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	18,942
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	13,766
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	23,865
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	31,796
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	30,904



	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,657
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	70
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	280
	Sum of Age/Sex disaggregates	350
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
Required only for DREAMS		



	countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	181
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	6,741
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	4,951
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver	



	Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening	



	Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	



	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+	



	Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	5,251
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	17,234
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	17,396



	period	
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator:	



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	721
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,235
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	681
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7,578
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The	



	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



TB_ART_TA	<p>TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment</p>	n/a
	<p>The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period</p>	277
	<p>The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period</p>	277
	<p>Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on</p>	



	ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	132
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented	10



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	131
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	643,386
	Screened for TB by Age/Sex: <15 Male	22,043
	Screened for TB by Age/Sex: 15+ Male	206,672
	Screened for TB by Age/Sex: <15 Female	23,208
	Screened for TB by Age/Sex: 15+ Female	213,754
	Screen Result: Screened Positive for TB	114,162
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for	114,062



	bacteriologic diagnosis of active TB	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	78,107
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	18,740
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	28,441
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	51,296
	Screened for TB by Age/Sex: <15 Male	1,382
	Screened for TB by Age/Sex: 15+ Male	20,591
	Screened for TB by Age/Sex: <15 Female	1,805
	Screened for TB by Age/Sex: 15+ Female	27,518
	Screen Results: Screened Positive for TB	3,693
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,693
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,842
	[Sub-disagg of Specimen Sent]	1,845



	Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	32,949
	By infants who received their first virologic HIV test between 2 and 12 months of age	33,439
	Sum of Infant Age disaggregates	66,388
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	666
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2	



	and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	1,065
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	1,271
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,530
	Sum of Infant Age disaggregates	2,801
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	14
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2	



	and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	80
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	847,788
	Age/Sex: 15-19 Male	12,649
	Age/Sex: 15-19 Female	19,379
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	38,514
	Aggregated Age/Sex: 15+ Male	284,821
	Aggregated Age/Sex: <15 Female	45,541
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	478,700
	Sum of Aggregated Age/Sex <15	84,055
	Sum of Aggregated Age/Sex 15+	763,521
	Sum of Aggregated Age/Sex disaggregates	847,576
	Age/Sex: <1	4,615
	Age/Sex: <1-9	22,879
	Age/Sex: 10-14 Male	11,706
	Age/Sex: 10-14 Female	14,553
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	32,093
	Age/Sex: 25-49 Male	107,036
	Age/Sex: 50+ Male	13,525
	Age/Sex: 20-24 Female	59,355
Age/Sex: 25-49 Female	166,001	



	Age/Sex: 50+ Female	19,510
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	66,516
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	384
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	524
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	908
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	2,651
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	24,281
	Aggregated Age/Sex: <15 Female	3,342
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	36,242
	Sum of Aggregated Age/Sex <15	5,993
	Sum of Aggregated Age/Sex 15+	60,523
	Sum of Aggregated Age/Sex disaggregates	66,516
	Age/Sex: <1	379
	Age/Sex: 1-9	1,251
	Age/Sex: 10-14 Male	463
	Age/Sex: 10-14 Female	850
Sum of Aggregated Age/Sex (<1		



	and 1-14) <15	
	Age/Sex: 20-24 Male	1,977
	Age/Sex: 25-49 Male	4,172
	Age/Sex: 50+ Male	368
	Age/Sex: 20-24 Female	3,403
	Age/Sex: 25-49 Female	8,242
	Age/Sex: 50+ Female	751
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	212,262
	By Age/Sex: <1	1,076
	By Age/Sex: 1-9	5,845
	By Age/Sex: 10-14 Male	2,146
	By Age/Sex: 15-19 Male	2,442
	By Age/Sex: 20-24 Male	5,176
	By Age/Sex: 25-49 Male	22,502
	By Age/Sex: 50+ Male	2,387
	By Age/Sex: 10-14 Female	2,542
	By Age/Sex: 15-19 Female	3,518
	By Age/Sex: 20-24 Female	9,699
	By Age/Sex: 25-49 Female	33,801
	By Age/Sex: 50+ Female	3,422
	Sum of Age/Sex disaggregates	87,635
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	11,695
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	71,004
	Aggregated Grouping by Age/Sex:	



	<1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	12,949
	Aggregated Grouping by Age/Sex: 15+ Female	116,612
	Sum of Aggregated Age/Sex disaggregates	212,260
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,287
	By Age/Sex: <1	
	By Age/Sex: 1-9	195
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	88
	By Age/Sex: 15-19 Male	101
	By Age/Sex: 20-24 Male	362
	By Age/Sex: 25-49 Male	719
	By Age/Sex: 50+ Male	71
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	162
	By Age/Sex: 15-19 Female	139
	By Age/Sex: 20-24 Female	599
	By Age/Sex: 25-49 Female	1,356
	By Age/Sex: 50+ Female	138
	Sum of Age/Sex disaggregates	3,735



	Aggregated Grouping by Age: <1	64
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	424
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	3,434
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	597
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	5,832
	Sum of Aggregated Age/Sex disaggregates	10,287
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	217,021



	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	501,955
	Numerator: Indication: Routine	129,853
	Numerator: Indication: Targeted	87,075
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication:	



	20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	192,665
	Denominator: Indication: Targeted	313,040
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by	



	Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	16,797
	Numerator Aggregated Age/Sex: 15+ Male	84,262
	Numerator Aggregated Age/Sex: <15 Female	16,671
	Numerator Aggregated Age/Sex: 15+ Female	99,034
	Denominator Aggregated Age/Sex: <15 Male	64,647
	Denominator Aggregated Age/Sex: 15+ Male	166,975
	Denominator Aggregated Age/Sex: <15 Female	64,588
	Denominator Aggregated Age/Sex: 15+ Female	216,294
TX_PVLS_TA	TX_PVLS_TA Percentage of ART	n/a



	patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,493
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,493
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	



	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	



	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	4,600
	Numerator: Indication: Targeted	8,893
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	4,600
	Denominator: Indication: Targeted	8,893
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	



	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	



	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	1,415
	Numerator Aggregated Age/Sex: 15+ Male	4,728
	Numerator Aggregated Age/Sex: <15 Female	1,373



	Numerator Aggregated Age/Sex: 15+ Female	5,977
	Denominator Aggregated Age/Sex: <15 Male	1,415
	Denominator Aggregated Age/Sex: 15+ Male	4,728
	Denominator Aggregated Age/Sex: <15 Female	1,373
	Denominator Aggregated Age/Sex: 15+ Female	5,977
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	121,315
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	129,732
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	753
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,906
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at	1,854



	12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,750
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,920
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16,410
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,077
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,187
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,647
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,076
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on	26,573



	treatment at 12 months after initiating ART	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,703
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	780
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,189
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,726
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,513



	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>4,778</p>
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>17,284</p>
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>2,242</p>
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>2,050</p>
	<p>Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the</p>	<p>2,502</p>



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,222
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,086
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,861
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,437
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39,967
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	7,513



	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67,416
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,072
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	43,098
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,183
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	73,211



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,848
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,848
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who	95



	are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	541
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
	Age/Sex: <1 (Denominator: Total	24



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	95



	those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated	190



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	541
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,455
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	444
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,602



	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	347
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,455
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	444
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,602
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported	520



	strengthening efforts, within the reporting period, by select cadre	
	By Graduates: Doctors	
	By Graduates: Nurses	
	By Graduates: Midwives	120
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	400
	Sum of Graduates disaggreagtes	520
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,077,104
	Number of HIV Test Kits purchased	51,000
	Number of HIV CD4 Reagents purchased	
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	
	Number of HIV ARVs purchased	4,026,104
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	5,229,941
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	240,365
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	

Approved





Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7422	Central Contraceptive Procurement	Private Contractor	U.S. Agency for International Development	GHP-State	0
7423	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
10203	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
10207	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,900,000
10219	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10220	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	2,166,326



			Control and Prevention		
10224	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	393,003
10225	Eastern Province Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,397,652
10227	Western Province Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,695,778
10235	University of Zambia School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	470,000
10236	University Teaching Hospital	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	7,844,967



			Prevention		
10238	Zambia National Blood Transfusion Service	Parastatal	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10241	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10260	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	0
10274	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,250,000
10354	Save the Children US	NGO	U.S. Agency for International Development	GHP-State	1,800,000
10364	Creative Associates International Inc	NGO	U.S. Agency for International Development	GHP-State	0
10726	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	2,000,000



10875	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	0
10984	Project Concern International	NGO	U.S. Department of Defense	GHP-State	4,104,946
11027	National HIV/AIDS/STI/TB Council - Zambia	Parastatal	U.S. Department of State/Bureau of African Affairs	GHP-State	234,000
11626	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
11627	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	1,932,480
11694	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
12267	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	0
12272	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
12276	Macha Research Trust, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
12821	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	0
12942	Project Concern International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13006	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13033	Population Council	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13076	John Snow, Inc.	Private Contractor	U.S. Department of Defense	GHP-State	0
13562	Chreso Ministries	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13580	CENTER FOR INFECTIOUS	NGO	U.S. Department of Health and	GHP-State	19,032,193



	DISEASE AND RESEARCH IN ZAMBIA		Human Services/Centers for Disease Control and Prevention		
13684	University of Zambia School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13731	Development Aid from People to People Humana Zambia	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13787	Churches Health Association of Zambia	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14339	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	150,000
14420	Lusaka Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,983,917



14421	Southern Provincial Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,651,263
14452	Population Services International	NGO	U.S. Department of Defense	GHP-State	1,500,000
14507	FHI 360	NGO	U.S. Department of Defense	GHP-State	5,142,304
16634	Expanded Church Response Trust	NGO	U.S. Agency for International Development	GHP-State	4,729,504
16656	TBD	TBD	Redacted	Redacted	Redacted
16690	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	900,000
16833	Emory University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	500,000
17100	Zambia Center for Communication Programs	NGO	U.S. Agency for International Development	GHP-State	1,307,000
17168	Expanded Church Response Trust	NGO	U.S. Agency for International	GHP-State	0



			Development		
17354	FHI 360	NGO	U.S. Agency for International Development	GHP-State	600,000
17355	(ASSIST) - Applying Science to Strengthen and Improve Systems Project	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
17356	FHI 360	NGO	U.S. Agency for International Development	GHP-State	441,775
17360	Education Development Center	NGO	U.S. Agency for International Development	GHP-State	0
17395	Luapula Foundation	NGO	U.S. Agency for International Development	GHP-State	0
17396	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	920,000
17399	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	10,352,512
17400	TBD	TBD	Redacted	Redacted	Redacted
17403	World Vision International	FBO	U.S. Agency for International Development	GHP-State	2,184,810
17410	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	7,936,403
17413	TBD	TBD	Redacted	Redacted	Redacted
17422	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,200,000



17425	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	6,590,500
17439	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	900,000
17448	Women and Law in Southern Africa	NGO	U.S. Agency for International Development	GHP-State	370,000
17449	Counterpart International	NGO	U.S. Agency for International Development	GHP-State	29,673
17477	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
17478	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
17479	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,145,918
17483	TBD	TBD	Redacted	Redacted	Redacted



17497	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,890,326
17499	TBD	TBD	Redacted	Redacted	Redacted
17500	University of Zambia	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17502	University of North Carolina	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17513	Ministry of Health, Zambia	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,542,894
17514	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,647,328



17523	New Partner	TBD	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	866,710
17573	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	300,000
17781	Johns Hopkins University Center for Communication Programs	University	U.S. Agency for International Development	GHP-State	0
17788	Development Aid from People to People Humana Zambia	NGO	U.S. Agency for International Development	GHP-State	6,211,118
17807	TBD	TBD	Redacted	Redacted	Redacted
17833	Population Council	NGO	U.S. Agency for International Development	GHP-State	0
17873	TBD	TBD	Redacted	Redacted	Redacted
17891	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	302,639



17897	TBD	TBD	Redacted	Redacted	Redacted
17927	Churches Health Association of Zambia	FBO	U.S. Agency for International Development	GHP-State	300,000
18159	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	107,515,847
18160	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	5,297,500
18161	Remote Medical International	Private Contractor	U.S. Agency for International Development	GHP-State	0
18251	TBD	TBD	Redacted	Redacted	Redacted
18259	TBD	TBD	Redacted	Redacted	Redacted
18263	UNICEF	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
18278	TBD	TBD	Redacted	Redacted	Redacted
18297	TBD	TBD	Redacted	Redacted	Redacted
18304	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	4,220,000
18322	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	500,000
18323	TBD	TBD	Redacted	Redacted	Redacted
18324	TBD	TBD	Redacted	Redacted	Redacted
18325	TBD	TBD	Redacted	Redacted	Redacted
18327	TBD	TBD	Redacted	Redacted	Redacted

Approved



18332	TBD	TBD	Redacted	Redacted	Redacted
18335	TBD	TBD	Redacted	Redacted	Redacted
18342	TBD	TBD	Redacted	Redacted	Redacted
18344	TBD	TBD	Redacted	Redacted	Redacted
18345	TBD	TBD	Redacted	Redacted	Redacted
18346	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	307,052
18457	TBD	TBD	Redacted	Redacted	Redacted



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7422	Mechanism Name: Central Contraceptive Procurement (CCP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Central Contraceptive Procurement	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7422		
Mechanism Name:	Central Contraceptive Procurement (CCP)		
Prime Partner Name:	Central Contraceptive Procurement		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7423	Mechanism Name: Supply Chain Management System Project (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7423		
Mechanism Name:	Supply Chain Management System Project (SCMS)		
Prime Partner Name:	Partnership for Supply Chain Management		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10203	Mechanism Name: The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10203		
Mechanism Name:	The Zambia Prevention, Care and Treatment Partnership II (ZPCT II)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10207	Mechanism Name: Twinning Centre
Funding Agency: HHS/HRSA	Procurement Type: Grant
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,900,000	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 1,900,000	
Funding Source	Funding Amount
GHP-State	1,900,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10207			
Mechanism Name: Twinning Centre			
Prime Partner Name: American International Health Alliance Twinning Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10219	Mechanism Name: EGPAF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10219		
Mechanism Name:	EGPAF		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21
PMTCT_ART_DSD	New on ART	11
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21
PMTCT_STAT_DSD	Number of new ANC and L&D clients	21



PMTCT_STAT_DSD	By: Known positives at entry	7
PMTCT_STAT_DSD	By: Number of new positives identified	14
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	21
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	19
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	12
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0



PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	19
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	83
HTC_TST_DSD	Age/sex: 10-14 Male	0
HTC_TST_DSD	Age/sex: 15-19 Male	0
HTC_TST_DSD	Age/sex: 20-24 Male	1
HTC_TST_DSD	Age/sex: 25-49 Male	17
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	1
HTC_TST_DSD	Age/sex: 15-19 Female	11
HTC_TST_DSD	Age/sex: 20-24 Female	9
HTC_TST_DSD	Age/sex: 25-49 Female	28
HTC_TST_DSD	Age/sex: 50+ Female	5
HTC_TST_DSD	Sum of Age/Sex disaggregates	72
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18

HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	53
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	71
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	83
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	11
HTC_TST_DSD	Service Delivery Point (Facility): VCT	83
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	145
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	47
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	92
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	19
PMTCT_EID_DSD	Sum of Infant Age disaggregates	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,612
TX_CURR_DSD	Age/Sex: 15-19 Male	43



TX_CURR_DSD	Age/Sex: 15-19 Female	127
TX_CURR_DSD	Sum of age/sex disaggregates	170
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	196
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,089
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	215
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,112
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	411
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,201
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,612
TX_CURR_DSD	Age/Sex: <1	14
TX_CURR_DSD	Age/Sex: <1-9	127
TX_CURR_DSD	Age/Sex: 10-14 Male	138
TX_CURR_DSD	Age/Sex: 10-14 Female	132
TX_CURR_DSD	Age/Sex: 20-24 Male	205
TX_CURR_DSD	Age/Sex: 25-49 Male	1,508
TX_CURR_DSD	Age/Sex: 50+ Male	168
TX_CURR_DSD	Age/Sex: 20-24 Female	91
TX_CURR_DSD	Age/Sex: 25-49 Female	882
TX_CURR_DSD	Age/Sex: 50+ Female	177
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	290
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	19
TX_NEW_DSD	By Age/Sex: 10-14 Male	9
TX_NEW_DSD	By Age/Sex: 15-19 Male	22
TX_NEW_DSD	By Age/Sex: 20-24 Male	2
TX_NEW_DSD	By Age/Sex: 25-49 Male	59
TX_NEW_DSD	By Age/Sex: 50+ Male	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	14
TX_NEW_DSD	By Age/Sex: 15-19 Female	5
TX_NEW_DSD	By Age/Sex: 20-24 Female	12
TX_NEW_DSD	By Age/Sex: 25-49 Female	123



TX_NEW_DSD	By Age/Sex: 50+ Female	12
TX_NEW_DSD	Sum of Age/Sex disaggregates	271
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	19
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	95
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	153
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	290
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	903
TX_PVLS_DSD	Numerator: Indication: Targeted	903
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	197
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	167
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	214
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	325
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	371
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	491
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	36
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	24
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	16



TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	91
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	142
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of	9



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	22



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	196
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	164
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	252

Implementing Mechanism Details

Mechanism ID: 10220	Mechanism Name: Intrahealth International
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,166,326	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,166,326	
Funding Source	Funding Amount
GHP-State	2,166,326

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	50,000
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: FSW	50,000
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners,



	and clients
--	-------------

Budget Code Information

Mechanism ID: 10220			
Mechanism Name: Intrahealth International			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	66,326	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	56,136
PP_PREV_DSD	Total number of people in the target population	65,896
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,481
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	19,959
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,968
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	32,728
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	332
KP_PREV_DSD	Total estimated number of key population in the catchment area	414
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	332
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	414
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	53,175
HTC_TST_DSD	Age/sex: 10-14 Male	1,534
HTC_TST_DSD	Age/sex: 15-19 Male	1,874
HTC_TST_DSD	Age/sex: 20-24 Male	1,871
HTC_TST_DSD	Age/sex: 25-49 Male	13,095
HTC_TST_DSD	Age/sex: 50+ Male	1,873



HTC_TST_DSD	Age/sex: 10-14 Female	2,296
HTC_TST_DSD	Age/sex: 15-19 Female	2,807
HTC_TST_DSD	Age/sex: 20-24 Female	2,807
HTC_TST_DSD	Age/sex: 25-49 Female	19,667
HTC_TST_DSD	Age/sex: 50+ Female	2,807
HTC_TST_DSD	Sum of Age/Sex disaggregates	50,631
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	59
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	222
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	222
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,570
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	222
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	98
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,357
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	340
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,552
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,717
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,828
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,078
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	6,380
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	46,795
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	53,175
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	98
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,245
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	143



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,380
HTC_TST_DSD	Test Result by Age: Positive: <1	17
HTC_TST_DSD	Test Result by Age: Positive: 1-9	80
HTC_TST_DSD	Age/sex: <1	635
HTC_TST_DSD	Age/sex: 1-9	1,909
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	53,175

Implementing Mechanism Details

Mechanism ID: 10224	Mechanism Name: National HIV/AIDS/STI/TB Council
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 393,003	
Applied Pipeline Amount: 46,997	
Total All Funding Sources and Applied Pipeline Amount: 440,000	
Funding Source	Funding Amount
GHP-State	393,003

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10224
Mechanism Name:	National HIV/AIDS/STI/TB Council
Prime Partner Name:	National HIV/AIDS/STI/TB Council - Zambia



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	290,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	103,003	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10225	Mechanism Name: EPHO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Province Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,397,652	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,397,652	
Funding Source	Funding Amount
GHP-State	4,397,652

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	50,719
---	--------



Budget Code Information

Mechanism ID: 10225			
Mechanism Name: EPHO Follow On			
Prime Partner Name: Eastern Province Health Office			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	220,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	381,872	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,445,780	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,949
PMTCT_ART_DSD	New on ART	196
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	282
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,949
PMTCT_STAT_DSD	Number of new ANC and L&D clients	21,949
PMTCT_STAT_DSD	By: Known positives at entry	1,083
PMTCT_STAT_DSD	By: Number of new positives identified	578
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,661
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	70
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	211
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	8



	known positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	203
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	320
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	126
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	4,111
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	9,157
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	8,555
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	556
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	286
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	126
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	4,111
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	9,157
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	8,555
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	7,821
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	234



VMMC_CIRC_DSD	By Age: 15-19	564
VMMC_CIRC_DSD	By Age: 20-24	3,321
VMMC_CIRC_DSD	By Age: 25-29	2,724
VMMC_CIRC_DSD	By Age: 30-49	909
VMMC_CIRC_DSD	By Age: 50+	69
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,188
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	7,821
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	7,568
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	253
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	4,309
PP_PREV_DSD	Total number of people in the target population	4,309
PP_PREV_DSD	Aggregated Age/sex: <15 Male	837
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,028
PP_PREV_DSD	Aggregated Age/sex: <15 Female	983
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,461
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	47,101
HTC_TST_DSD	Age/sex: 10-14 Male	1,533
HTC_TST_DSD	Age/sex: 15-19 Male	3,896
HTC_TST_DSD	Age/sex: 20-24 Male	5,407
HTC_TST_DSD	Age/sex: 25-49 Male	6,452
HTC_TST_DSD	Age/sex: 50+ Male	1,277
HTC_TST_DSD	Age/sex: 10-14 Female	1,567
HTC_TST_DSD	Age/sex: 15-19 Female	5,037
HTC_TST_DSD	Age/sex: 20-24 Female	8,634
HTC_TST_DSD	Age/sex: 25-49 Female	10,840
HTC_TST_DSD	Age/sex: 50+ Female	1,712
HTC_TST_DSD	Sum of Age/Sex disaggregates	46,355
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	103



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	120
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	274
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	398
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	88
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	233
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	365
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	715
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	120
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,959
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,470
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,289
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,383
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,248
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	42,853
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	47,101
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	115
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	822
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	136
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,479
HTC_TST_DSD	Test Result by Age: Positive: <1	2
HTC_TST_DSD	Test Result by Age: Positive: 1-9	32
HTC_TST_DSD	Age/sex: <1	4
HTC_TST_DSD	Age/sex: 1-9	742
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	6,408

HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	22,880
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,576
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	5
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	6,295
HTC_TST_DSD	Service Delivery Point (Facility): VCT	6,082
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	158
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,481
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	914
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	302
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	466
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	466
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	208
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	207
GEND_GBV_DSD	Number of people receiving post-GBV care	2,000
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,151
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,151
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	16

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	465
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	648
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	48,580
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,917
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	17,704
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,330
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	26,629
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,598
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,598
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,254
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,220
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	124
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	318
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	260

PMTCT_EID_DSD	Sum of Infant Age disaggregates	578
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	4
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	49,675
TX_CURR_DSD	Age/Sex: 15-19 Male	2,294
TX_CURR_DSD	Age/Sex: 15-19 Female	4,306
TX_CURR_DSD	Sum of age/sex disaggregates	6,600
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,006
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	17,502
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,623
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	27,544
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,629
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	45,046
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	49,675
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	428
TX_CURR_DSD	Age/Sex: 10-14 Male	1,948
TX_CURR_DSD	Age/Sex: 10-14 Female	2,253
TX_CURR_DSD	Age/Sex: 20-24 Male	6,120
TX_CURR_DSD	Age/Sex: 25-49 Male	9,010
TX_CURR_DSD	Age/Sex: 50+ Male	690
TX_CURR_DSD	Age/Sex: 20-24 Female	10,305
TX_CURR_DSD	Age/Sex: 25-49 Female	11,193
TX_CURR_DSD	Age/Sex: 50+ Female	1,128
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,599
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	46
TX_NEW_DSD	By Age/Sex: 10-14 Male	153



TX_NEW_DSD	By Age/Sex: 15-19 Male	257
TX_NEW_DSD	By Age/Sex: 20-24 Male	468
TX_NEW_DSD	By Age/Sex: 25-49 Male	728
TX_NEW_DSD	By Age/Sex: 50+ Male	248
TX_NEW_DSD	By Age/Sex: 10-14 Female	195
TX_NEW_DSD	By Age/Sex: 15-19 Female	398
TX_NEW_DSD	By Age/Sex: 20-24 Female	762
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,079
TX_NEW_DSD	By Age/Sex: 50+ Female	265
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,553
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	162
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,697
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	236
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,504
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,599
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	15,715
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	15,715
TX_PVLS_DSD	Numerator: Indication: Routine	13,156
TX_PVLS_DSD	Numerator: Indication: Targeted	2,559
TX_PVLS_DSD	Denominator: Indication: Routine	13,156
TX_PVLS_DSD	Denominator: Indication: Targeted	2,559
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	817
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,321
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,094
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	8,483
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	649
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,332



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,065
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	8,669
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,536
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,536
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	159
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	428
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	553
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	908
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	215
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	627



TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	839
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,327
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	227
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	159
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	428
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	553
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of	908



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	119
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	215
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	627
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	839
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,327
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	227
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	284



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,887
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	341
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,024
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	357
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,814
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	431
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,934

Implementing Mechanism Details

Mechanism ID: 10227	Mechanism Name: WPHO Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Western Province Health Office	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,695,778	
Applied Pipeline Amount: 404,738	
Total All Funding Sources and Applied Pipeline Amount: 4,100,516	
Funding Source	Funding Amount
GHP-State	3,695,778

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID:	10227
Mechanism Name:	WPHO Follow on
Prime Partner Name:	Western Province Health Office



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	550,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	295,555	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	73,898	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	169,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	184,726	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	74,007	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	221,672	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	125,614	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,300,358	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	250,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,536
PMTCT_ART_DSD	New on ART	2,359
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	736
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,540
PMTCT_ART_TA	New on ART	184
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	79
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,536
PMTCT_STAT_DSD	Number of new ANC and L&D clients	3,536
PMTCT_STAT_DSD	By: Known positives at entry	143
PMTCT_STAT_DSD	By: Number of new positives identified	206
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	349
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	4
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	11
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	60
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	1



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	11
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	47
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	177
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	354
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,237
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	1,768
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	84
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	131
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	177
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	354
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	1,237
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	1,768
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,540
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,540
PMTCT_STAT_TA	By: Known positives at entry	300
PMTCT_STAT_TA	By: Number of new positives identified	446
PMTCT_STAT_TA	Sum of Positives Status disaggregates	746
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	5
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	34
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	85
PMTCT_STAT_TA	Required only for DREAMS countries - By new	12



	positives: <15	
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	50
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	114
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	350
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	706
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	2,471
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	4,013
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	176
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	270
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	350
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	706
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	2,472
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	4,012
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,290
VMMC_CIRC_DSD	By Age: 10-14	1,789
VMMC_CIRC_DSD	By Age: 15-19	1,592
VMMC_CIRC_DSD	By Age: 20-24	913
VMMC_CIRC_DSD	By Age: 25-29	608
VMMC_CIRC_DSD	By Age: 30-49	265
VMMC_CIRC_DSD	By Age: 50+	123



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,417
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	5,290
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	5,290
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	65,011
PP_PREV_TA	Total number of people in the target population	221,419
PP_PREV_TA	Aggregated Age/sex: <15 Male	3,106
PP_PREV_TA	Aggregated Age/sex: 15+ Male	27,883
PP_PREV_TA	Aggregated Age/sex: <15 Female	3,509
PP_PREV_TA	Aggregated Age/sex: 15+ Female	30,513
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	604
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,733
HTC_TST_TA	Age/sex: 10-14 Male	1,103
HTC_TST_TA	Age/sex: 15-19 Male	2,564
HTC_TST_TA	Age/sex: 20-24 Male	5,499
HTC_TST_TA	Age/sex: 25-49 Male	6,600
HTC_TST_TA	Age/sex: 50+ Male	773
HTC_TST_TA	Age/sex: 10-14 Female	1,470
HTC_TST_TA	Age/sex: 15-19 Female	3,302
HTC_TST_TA	Age/sex: 20-24 Female	6,240
HTC_TST_TA	Age/sex: 25-49 Female	6,980
HTC_TST_TA	Age/sex: 50+ Female	1,100
HTC_TST_TA	Sum of Age/Sex disaggregates	35,631
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	113
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	259
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	543



HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	654
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	71
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	151
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	336
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	625
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	700
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	115
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,792
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	15,776
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,987
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,178
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,779
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	32,954
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	36,733
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	171
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,582
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	196
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,724
HTC_TST_TA	Test Result by Age: Positive: <1	38
HTC_TST_TA	Test Result by Age: Positive: 1-9	68
HTC_TST_TA	Age/sex: <1	368
HTC_TST_TA	Age/sex: 1-9	734
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	511
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	864
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	21

HTC_TST_TA	Service Delivery Point (Facility): Other PITC	217
HTC_TST_TA	Service Delivery Point (Facility): VCT	24,543
HTC_TST_TA	Service Delivery Point (Facility): VMMC	500
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	8,156
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,012
HTC_TST_TA	Service Delivery Point (Facility): Index testing	909
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,865
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,865
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	96
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	800
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	108
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	861
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	597
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	597
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	245



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	279
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	79
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	79
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	24,556



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,180
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	10,589
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,286
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	11,501
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,346
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,346
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	971
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	375
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,811
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	278
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,544
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	313
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1,676
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	1,853
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,853
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	570
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,277
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	733
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	648
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,381
PMTCT_EID_TA	By infants who received a virologic test within 2 months	298



	of birth	
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	167
PMTCT_EID_TA	Sum of Infant Age disaggregates	465
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,602
TX_CURR_DSD	Age/Sex: 15-19 Male	1,933
TX_CURR_DSD	Age/Sex: 15-19 Female	2,486
TX_CURR_DSD	Sum of age/sex disaggregates	4,419
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,357
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,164
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,349
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	12,732
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,706
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	24,896
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,602
TX_CURR_DSD	Age/Sex: <1	279
TX_CURR_DSD	Age/Sex: <1-9	551
TX_CURR_DSD	Age/Sex: 10-14 Male	830
TX_CURR_DSD	Age/Sex: 10-14 Female	1,104
TX_CURR_DSD	Age/Sex: 20-24 Male	4,143
TX_CURR_DSD	Age/Sex: 25-49 Male	4,954
TX_CURR_DSD	Age/Sex: 50+ Male	554
TX_CURR_DSD	Age/Sex: 20-24 Female	4,694
TX_CURR_DSD	Age/Sex: 25-49 Female	5,246
TX_CURR_DSD	Age/Sex: 50+ Female	828
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,271



TX_CURR_TA	Age/Sex: 15-19 Male	300
TX_CURR_TA	Age/Sex: 15-19 Female	384
TX_CURR_TA	Sum of Age/Sex disaggregations	684
TX_CURR_TA	Aggregated Age/Sex: <15 Male	216
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,813
TX_CURR_TA	Aggregated Age/Sex: <15 Female	225
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,017
TX_CURR_TA	Sum of Aggregated Age/Sex <15	441
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,830
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,271
TX_CURR_TA	Age/Sex: <1	44
TX_CURR_TA	Age/Sex: 1-9	85
TX_CURR_TA	Age/Sex: 10-14 Male	126
TX_CURR_TA	Age/Sex: 10-14 Female	171
TX_CURR_TA	Age/Sex: 20-24 Male	641
TX_CURR_TA	Age/Sex: 25-49 Male	769
TX_CURR_TA	Age/Sex: 50+ Male	85
TX_CURR_TA	Age/Sex: 20-24 Female	726
TX_CURR_TA	Age/Sex: 25-49 Female	812
TX_CURR_TA	Age/Sex: 50+ Female	128
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,503
TX_NEW_DSD	By Age/Sex: <1	79
TX_NEW_DSD	By Age/Sex: 1-9	156
TX_NEW_DSD	By Age/Sex: 10-14 Male	239
TX_NEW_DSD	By Age/Sex: 15-19 Male	554
TX_NEW_DSD	By Age/Sex: 20-24 Male	784
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,071
TX_NEW_DSD	By Age/Sex: 50+ Male	155
TX_NEW_DSD	By Age/Sex: 10-14 Female	316
TX_NEW_DSD	By Age/Sex: 15-19 Female	710
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,043



TX_NEW_DSD	By Age/Sex: 25-49 Female	1,156
TX_NEW_DSD	By Age/Sex: 50+ Female	240
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,268
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	365
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,711
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	417
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,010
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,503
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,223
TX_NEW_TA	By Age/Sex: 1-9	23
TX_NEW_TA	By Age/Sex: 10-14 Male	37
TX_NEW_TA	By Age/Sex: 15-19 Male	87
TX_NEW_TA	By Age/Sex: 20-24 Male	183
TX_NEW_TA	By Age/Sex: 25-49 Male	214
TX_NEW_TA	By Age/Sex: 50+ Male	26
TX_NEW_TA	By Age/Sex: 10-14 Female	50
TX_NEW_TA	By Age/Sex: 15-19 Female	110
TX_NEW_TA	By Age/Sex: 20-24 Female	209
TX_NEW_TA	By Age/Sex: 25-49 Female	234
TX_NEW_TA	By Age/Sex: 50+ Female	37
TX_NEW_TA	Sum of Age/Sex disaggregates	1,187
TX_NEW_TA	Aggregated Grouping by Age: <1	13
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	59
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	527
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	63
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	574
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,223
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,039



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,039
TX_PVLS_DSD	Numerator: Indication: Routine	7,648
TX_PVLS_DSD	Numerator: Indication: Targeted	391
TX_PVLS_DSD	Denominator: Indication: Routine	7,503
TX_PVLS_DSD	Denominator: Indication: Targeted	536
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	592
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,230
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	677
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,540
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	592
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,230
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	677
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	3,540
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,894
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,894
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	60
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	86
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	204
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults	433



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	520
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	114
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	491
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	554
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	90
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	86



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	204
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	433
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	519
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	260
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	491



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	554
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	145
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,217
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	163
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,369
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	145
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,217
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	163



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,369

Implementing Mechanism Details

Mechanism ID: 10235	Mechanism Name: UNZA SOM Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 470,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 470,000	
Funding Source	Funding Amount
GHP-State	470,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10235
Mechanism Name:	UNZA SOM Follow-on
Prime Partner Name:	University of Zambia School of Medicine



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	220,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10236	Mechanism Name: University Teaching Hospital (Combined HAP & LAB)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Teaching Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 7,844,967	
Applied Pipeline Amount: 779,213	
Total All Funding Sources and Applied Pipeline Amount: 8,624,180	
Funding Source	Funding Amount
GHP-State	7,844,967

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 10236			
Mechanism Name: University Teaching Hospital (Combined HAP & LAB)			
Prime Partner Name: University Teaching Hospital			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	455,123	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	365,371	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	663,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	19,031	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	272,424	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	913,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	2,956,164	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,208
PMTCT_ART_DSD	New on ART	235
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,624
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,208
PMTCT_STAT_DSD	Number of new ANC and L&D clients	35,477
PMTCT_STAT_DSD	By: Known positives at entry	7,624
PMTCT_STAT_DSD	By: Number of new positives identified	235
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	7,859
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	80
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	235
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	1,255
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	0



	<15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	3,993
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	7,091
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	24,393
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	6,134
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	142
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2,612
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	4,639
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	15,957
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,334
PP_PREV_DSD	Total number of people in the target population	3,334
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,100
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	2,234
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	46,259



HTC_TST_DSD	Age/sex: 10-14 Male	720
HTC_TST_DSD	Age/sex: 15-19 Male	574
HTC_TST_DSD	Age/sex: 20-24 Male	1,493
HTC_TST_DSD	Age/sex: 25-49 Male	12,327
HTC_TST_DSD	Age/sex: 50+ Male	352
HTC_TST_DSD	Age/sex: 10-14 Female	976
HTC_TST_DSD	Age/sex: 15-19 Female	671
HTC_TST_DSD	Age/sex: 20-24 Female	2,007
HTC_TST_DSD	Age/sex: 25-49 Female	13,947
HTC_TST_DSD	Age/sex: 50+ Female	329
HTC_TST_DSD	Sum of Age/Sex disaggregates	33,396
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	79
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	163
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	405
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,093
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	74
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	106
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	106
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	360
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,831
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	63
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,193
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,746
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,366
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,954
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	14,559
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	31,700
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	46,259



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	556
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,735
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	608
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,360
HTC_TST_DSD	Test Result by Age: Positive: <1	287
HTC_TST_DSD	Test Result by Age: Positive: 1-9	692
HTC_TST_DSD	Age/sex: <1	6,322
HTC_TST_DSD	Age/sex: 1-9	6,541
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	31,259
HTC_TST_DSD	Service Delivery Point (Facility): VCT	500
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	12,000
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,500
GEND_GBV_DSD	Number of people receiving post-GBV care	2,000
GEND_GBV_DSD	Age/Sex: <10 Male	5
GEND_GBV_DSD	Age/Sex: 10-14 Male	10
GEND_GBV_DSD	Age/Sex: 20-24 Male	0
GEND_GBV_DSD	Age/Sex: 25-49 Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	300
GEND_GBV_DSD	Age/Sex: 10-14 Female	685
GEND_GBV_DSD	Age/Sex: 20-24 Female	0
GEND_GBV_DSD	Age/Sex: 25-49 Female	0
GEND_GBV_DSD	Age/Sex: 50+ Female	0
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	1,000
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,000
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	600
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,000



GEND_GBV_DSD	Age/Sex: 15-19 male	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,400
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	520
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	410
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Social Protection Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	520
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	406
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	40
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,200
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	70
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	80
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	750
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	750
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	150
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The	225



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	150
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	225
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	9,275
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,753
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,882
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,752
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,888
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	350
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	350
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	350
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,482
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,358
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,840
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	275
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	118
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,961



TX_CURR_DSD	Age/Sex: 15-19 Male	450
TX_CURR_DSD	Age/Sex: 15-19 Female	450
TX_CURR_DSD	Sum of age/sex disaggregates	900
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	282
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,201
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	282
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,196
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	564
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,397
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,961
TX_CURR_DSD	Age/Sex: <1	39
TX_CURR_DSD	Age/Sex: <1-9	237
TX_CURR_DSD	Age/Sex: 10-14 Male	143
TX_CURR_DSD	Age/Sex: 10-14 Female	145
TX_CURR_DSD	Age/Sex: 20-24 Male	850
TX_CURR_DSD	Age/Sex: 25-49 Male	891
TX_CURR_DSD	Age/Sex: 50+ Male	10
TX_CURR_DSD	Age/Sex: 20-24 Female	850
TX_CURR_DSD	Age/Sex: 25-49 Female	886
TX_CURR_DSD	Age/Sex: 50+ Female	10
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,742
TX_NEW_DSD	By Age/Sex: <1	20
TX_NEW_DSD	By Age/Sex: 1-9	122
TX_NEW_DSD	By Age/Sex: 10-14 Male	52
TX_NEW_DSD	By Age/Sex: 15-19 Male	100
TX_NEW_DSD	By Age/Sex: 20-24 Male	230
TX_NEW_DSD	By Age/Sex: 25-49 Male	408
TX_NEW_DSD	By Age/Sex: 50+ Male	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	52
TX_NEW_DSD	By Age/Sex: 15-19 Female	100
TX_NEW_DSD	By Age/Sex: 20-24 Female	230



TX_NEW_DSD	By Age/Sex: 25-49 Female	408
TX_NEW_DSD	By Age/Sex: 50+ Female	10
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,600
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	123
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	748
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	123
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	748
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,742
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,240
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,240
TX_PVLS_DSD	Numerator: Indication: Routine	1,240
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	1,240
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	282
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	338
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	282
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	338
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	282
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	338
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	282
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	338
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,230
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,264



TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	300
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	319
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	300
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	201
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	317
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



	months after initiating ART	
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	343
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	93
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	130
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,014
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	136



TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	455
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,603
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	127
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	296
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	819
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	818



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,405
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	156
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,561

Implementing Mechanism Details

Mechanism ID: 10238	Mechanism Name: TBD (ZNBTS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia National Blood Transfusion Service	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



GHP-State	0
-----------	---

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10238			
Mechanism Name: TBD (ZNBTS)			
Prime Partner Name: Zambia National Blood Transfusion Service			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	987



HTC_TST_DSD	Age/sex: 10-14 Male	3
HTC_TST_DSD	Age/sex: 15-19 Male	5
HTC_TST_DSD	Age/sex: 20-24 Male	20
HTC_TST_DSD	Age/sex: 25-49 Male	157
HTC_TST_DSD	Age/sex: 50+ Male	21
HTC_TST_DSD	Age/sex: 10-14 Female	5
HTC_TST_DSD	Age/sex: 15-19 Female	13
HTC_TST_DSD	Age/sex: 20-24 Female	35
HTC_TST_DSD	Age/sex: 25-49 Female	141
HTC_TST_DSD	Age/sex: 50+ Female	11
HTC_TST_DSD	Sum of Age/Sex disaggregates	411
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	16
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	2
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	491
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	488
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	979
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	987
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	42
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	42



HTC_TST_DSD	Service Delivery Point (Community): Index testing	987
-------------	---	-----

Implementing Mechanism Details

Mechanism ID: 10241	Mechanism Name: CRS FBO follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10241		
Mechanism Name:	CRS FBO follow on		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	349
PP_PREV_DSD	Total number of people in the target population	349
PP_PREV_DSD	Aggregated Age/sex: <15 Male	17
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	110
PP_PREV_DSD	Aggregated Age/sex: <15 Female	18
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	204
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	882
HTC_TST_DSD	Age/sex: 10-14 Male	9
HTC_TST_DSD	Age/sex: 15-19 Male	28
HTC_TST_DSD	Age/sex: 20-24 Male	96
HTC_TST_DSD	Age/sex: 25-49 Male	126
HTC_TST_DSD	Age/sex: 50+ Male	28
HTC_TST_DSD	Age/sex: 10-14 Female	9
HTC_TST_DSD	Age/sex: 15-19 Female	52
HTC_TST_DSD	Age/sex: 20-24 Female	180
HTC_TST_DSD	Age/sex: 25-49 Female	232
HTC_TST_DSD	Age/sex: 50+ Female	52
HTC_TST_DSD	Sum of Age/Sex disaggregates	812



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	22
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	44
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	318
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	44
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	476
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	88
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	794
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	882
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	32
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	48
HTC_TST_DSD	Test Result by Age: Positive: <1	4
HTC_TST_DSD	Test Result by Age: Positive: 1-9	4
HTC_TST_DSD	Age/sex: <1	30
HTC_TST_DSD	Age/sex: 1-9	40



HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	88
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	132
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	88
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	69
HTC_TST_DSD	Service Delivery Point (Facility): VCT	441
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	44
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	20
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	133
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	133
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	67
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	19
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The	6



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,763
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	238
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,500
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	238
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	2,787
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,191
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,191
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	834
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	297
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	60
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,417
TX_CURR_DSD	Age/Sex: 15-19 Male	45
TX_CURR_DSD	Age/Sex: 15-19 Female	83
TX_CURR_DSD	Sum of age/sex disaggregates	128
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	71
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	510



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	71
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	765
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	142
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,275
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,417
TX_CURR_DSD	Age/Sex: <1	50
TX_CURR_DSD	Age/Sex: <1-9	64
TX_CURR_DSD	Age/Sex: 10-14 Male	14
TX_CURR_DSD	Age/Sex: 10-14 Female	14
TX_CURR_DSD	Age/Sex: 20-24 Male	156
TX_CURR_DSD	Age/Sex: 25-49 Male	200
TX_CURR_DSD	Age/Sex: 50+ Male	45
TX_CURR_DSD	Age/Sex: 20-24 Female	290
TX_CURR_DSD	Age/Sex: 25-49 Female	373
TX_CURR_DSD	Age/Sex: 50+ Female	83
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	332
TX_NEW_DSD	By Age/Sex: <1	12
TX_NEW_DSD	By Age/Sex: 1-9	15
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	10
TX_NEW_DSD	By Age/Sex: 20-24 Male	37
TX_NEW_DSD	By Age/Sex: 25-49 Male	48
TX_NEW_DSD	By Age/Sex: 50+ Male	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	19
TX_NEW_DSD	By Age/Sex: 20-24 Female	68
TX_NEW_DSD	By Age/Sex: 25-49 Female	88
TX_NEW_DSD	By Age/Sex: 50+ Female	19
TX_NEW_DSD	Sum of Age/Sex disaggregates	305
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	120



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	178
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	332
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	543
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	543
TX_PVLS_DSD	Numerator: Indication: Routine	489
TX_PVLS_DSD	Numerator: Indication: Targeted	54
TX_PVLS_DSD	Denominator: Indication: Routine	489
TX_PVLS_DSD	Denominator: Indication: Targeted	54
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	27
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	171
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	27
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	318
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	27
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	171
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	27
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	318
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	589
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	589
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25



TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	120
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	133
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11



TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	120
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of	53



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	106
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	186
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	345
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	29



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	186
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	345

Implementing Mechanism Details

Mechanism ID: 10260	Mechanism Name: USAID DELIVER PROJECT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 10260			
Mechanism Name: USAID DELIVER PROJECT			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10274		Mechanism Name: MARCH Zambia	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: New Partner			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 1,250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,250,000	
Funding Source	Funding Amount
GHP-State	1,250,000



Cross-Cutting Budget Attribution(s)

Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID: 10274			
Mechanism Name: MARCH Zambia			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	850,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
------------------	-------	------



PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	117,787
PP_PREV_DSD	Total number of people in the target population	117,787
PP_PREV_DSD	Aggregated Age/sex: <15 Male	7,968
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	45,035
PP_PREV_DSD	Aggregated Age/sex: <15 Female	9,746
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	55,038
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	130
KP_PREV_DSD	Total estimated number of key population in the catchment area	130
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	40
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	90
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	40
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	90

Implementing Mechanism Details

Mechanism ID: 10354	Mechanism Name: Zambia OVC System Strengthening Program (ZOVS) / Zambia Rising
----------------------------	---



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Save the Children US	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,800,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,800,000	
Funding Source	Funding Amount
GHP-State	1,800,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	850,000
----------------------------	---------

Budget Code Information

Mechanism ID: 10354			
Mechanism Name: Zambia OVC System Strengthening Program (ZOVSS) / Zambia Rising			
Prime Partner Name: Save the Children US			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,800,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10364	Mechanism Name: Read to Succeed (previously
----------------------------	--

Approved



	ISEP)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Creative Associates International Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10364		
Mechanism Name:	Read to Succeed (previously ISEP)		
Prime Partner Name:	Creative Associates International Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10726	Mechanism Name: The Thrive Project
----------------------------	---



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,000,000	
Funding Source	Funding Amount
GHP-State	2,000,000

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	1,500,000
Food and Nutrition: Commodities	500,000

Budget Code Information

Mechanism ID: 10726			
Mechanism Name: The Thrive Project			
Prime Partner Name: Program for Appropriate Technology in Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,090,372	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	309,628	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,000
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,550
OVC_SERV_DSD	Age/Sex: 18+ Male	744
OVC_SERV_DSD	Age/Sex: 18+ Female	764
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,508
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,855
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,786
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	850

Implementing Mechanism Details

Mechanism ID: 10875	Mechanism Name: United Nations High Commissioner for Refugees/PRM
Funding Agency: State/PRM	Procurement Type: Umbrella Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10875		
Mechanism Name:	United Nations High Commissioner for Refugees/PRM		
Prime Partner Name:	United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,501
PP_PREV_DSD	Total number of people in the target population	21,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	2,250
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	5,661
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,300
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	7,290



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,755
HTC_TST_DSD	Age/sex: 10-14 Male	180
HTC_TST_DSD	Age/sex: 15-19 Male	264
HTC_TST_DSD	Age/sex: 20-24 Male	126
HTC_TST_DSD	Age/sex: 25-49 Male	39
HTC_TST_DSD	Age/sex: 50+ Male	18
HTC_TST_DSD	Age/sex: 10-14 Female	372
HTC_TST_DSD	Age/sex: 15-19 Female	300
HTC_TST_DSD	Age/sex: 20-24 Female	132
HTC_TST_DSD	Age/sex: 25-49 Female	66
HTC_TST_DSD	Age/sex: 50+ Female	12
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,509
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	39
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	60
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	9
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	69
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	75
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	30
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	15
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	12
HTC_TST_DSD	Test Result by Age: Positive: <1	9
HTC_TST_DSD	Test Result by Age: Positive: 1-9	51
HTC_TST_DSD	Age/sex: <1	21
HTC_TST_DSD	Age/sex: 1-9	225

Implementing Mechanism Details

Mechanism ID: 10984	Mechanism Name: DOD Project Concern International PCI
Funding Agency: DOD	Procurement Type: Grant



Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,104,946	
Applied Pipeline Amount: 400,000	
Total All Funding Sources and Applied Pipeline Amount: 4,504,946	
Funding Source	Funding Amount
GHP-State	4,104,946

Cross-Cutting Budget Attribution(s)

Economic Strengthening	100,000
Education	300,000
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Condom programming	20,000

Budget Code Information

Mechanism ID:	10984		
Mechanism Name:	DOD Project Concern International PCI		
Prime Partner Name:	Project Concern International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	914,946	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	550,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	400,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	20,000
PP_PREV_TA	Total number of people in the target population	25,670
PP_PREV_TA	Aggregated Age/sex: <15 Male	989
PP_PREV_TA	Aggregated Age/sex: 15+ Male	9,211
PP_PREV_TA	Aggregated Age/sex: <15 Female	1,425



PP_PREV_TA	Aggregated Age/sex: 15+ Female	8,375
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,305
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,040
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,990
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,136
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,139
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,176
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,129
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,305
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	142
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	679
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	155
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	699
HTC_TST_DSD	Service Delivery Point (Community): Index testing	2,052
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	2,831
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	7,422
GEND_GBV_TA	Number of people receiving post-GBV care	225
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	185
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	40
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	40
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	10,800



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 18+ Male	530
OVC_SERV_DSD	Age/Sex: 18+ Female	551
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,081
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,762
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,957

Implementing Mechanism Details

Mechanism ID: 11027	Mechanism Name: National AIDS Council Joint Financing Arrangement
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: National HIV/AIDS/STI/TB Council - Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: State/AF

Total All Funding Sources: 234,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 234,000	
Funding Source	Funding Amount
GHP-State	234,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	11027
Mechanism Name:	National AIDS Council Joint Financing Arrangement
Prime Partner Name:	National HIV/AIDS/STI/TB Council - Zambia



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	234,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11626	Mechanism Name: Jhpiego
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11626
Mechanism Name: Jhpiego
Prime Partner Name: JHPIEGO



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11627	Mechanism Name: DAO Lusaka
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,932,480	
Applied Pipeline Amount: 1,487,601	
Total All Funding Sources and Applied Pipeline Amount: 3,420,081	
Funding Source	Funding Amount
GHP-State	1,932,480

Cross-Cutting Budget Attribution(s)

Human Resources for Health	50,000
Construction	1,532,480
Renovation	300,000
Water	50,000

Budget Code Information

Mechanism ID: 11627			
Mechanism Name: DAO Lusaka			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,932,480	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11694	Mechanism Name: CDC Technical Assistance - SMDP & FETP
Funding Agency: HHS/CDC	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11694



Mechanism Name: CDC Technical Assistance - SMDP & FETP			
Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12267	Mechanism Name: Mawa (formerly ZERS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 12267			
Mechanism Name: Mawa (formerly ZERS)			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	102,702
OVC_SERV_DSD	Age/Sex: 18+ Male	21,876
OVC_SERV_DSD	Age/Sex: 18+ Female	22,440
OVC_SERV_DSD	Sum of Age/Sex disaggregates	44,316
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	29,167
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	29,219

Implementing Mechanism Details

Mechanism ID: 12272	Mechanism Name: PEPFAR OVC Small Grants
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12272		
Mechanism Name:	PEPFAR OVC Small Grants		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,500
OVC_SERV_DSD	Age/Sex: 18+ Male	277
OVC_SERV_DSD	Age/Sex: 18+ Female	330
OVC_SERV_DSD	Sum of Age/Sex disaggregates	607
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	443
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	450

Implementing Mechanism Details

Mechanism ID: 12276	Mechanism Name: Macha Research Trust, Inc
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Macha Research Trust, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12276			
Mechanism Name: Macha Research Trust, Inc			
Prime Partner Name: Macha Research Trust, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12821	Mechanism Name: STEP UP
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12821			
Mechanism Name: STEP UP			
Prime Partner Name: Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12942	Mechanism Name: PROJECT CONCERN INTERNATIONAL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12942		
Mechanism Name:	PROJECT CONCERN INTERNATIONAL		
Prime Partner Name:	Project Concern International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13006	Mechanism Name: CIDRZ - Community Compact
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13006			
Mechanism Name: CIDRZ - Community Compact			
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13033	Mechanism Name: POPULATION COUNCIL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13033		
Mechanism Name:	POPULATION COUNCIL		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13076	Mechanism Name: JSI Logistics Services
----------------------------	---



Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13076			
Mechanism Name: JSI Logistics Services			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13562	Mechanism Name: CHRESO Ministries
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Chreso Ministries	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13562		
Mechanism Name:	CHRESO Ministries		
Prime Partner Name:	Chreso Ministries		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,516
PMTCT_ART_DSD	New on ART	94
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	79
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,516
PMTCT_STAT_DSD	Number of new ANC and L&D clients	4,997
PMTCT_STAT_DSD	By: Known positives at entry	474
PMTCT_STAT_DSD	By: Number of new positives identified	273
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	747
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	14
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	28
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	92
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	33
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	108



	known positives: 20-24	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	21
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	215
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,893
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	2,068
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	72
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	140
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	131
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	14
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	68
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	145
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	523
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	597
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	62
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	75,225
PP_PREV_DSD	Total number of people in the target population	57,030
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,607
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	31,724
PP_PREV_DSD	Aggregated Age/sex: <15 Female	5,687
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	32,207
KP_PREV_DSD	Number of key populations reached with individual	2,700



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	2,700
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,700
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,700
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,036
HTC_TST_DSD	Age/sex: 10-14 Male	365
HTC_TST_DSD	Age/sex: 15-19 Male	671
HTC_TST_DSD	Age/sex: 20-24 Male	1,244
HTC_TST_DSD	Age/sex: 25-49 Male	2,241
HTC_TST_DSD	Age/sex: 50+ Male	421
HTC_TST_DSD	Age/sex: 10-14 Female	390
HTC_TST_DSD	Age/sex: 15-19 Female	811
HTC_TST_DSD	Age/sex: 20-24 Female	1,541
HTC_TST_DSD	Age/sex: 25-49 Female	2,113
HTC_TST_DSD	Age/sex: 50+ Female	491
HTC_TST_DSD	Sum of Age/Sex disaggregates	10,288
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	27
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	88
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	356
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	48
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	18



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	43
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	155
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	346
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	51
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	716
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,691
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	799
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,830
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,515
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,521
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,036
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	72
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	537
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	90
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	556
HTC_TST_DSD	Test Result by Age: Positive: <1	5
HTC_TST_DSD	Test Result by Age: Positive: 1-9	52
HTC_TST_DSD	Age/sex: <1	143
HTC_TST_DSD	Age/sex: 1-9	605
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	37
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	27
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	23
HTC_TST_DSD	Service Delivery Point (Facility): VCT	10,572
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	170
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	207



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,738
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	788
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	884
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	350
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	129
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	144
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	199



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	21,954
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	661
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	8,294
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	946
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	12,053
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	75
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	44
PMTCT_EID_DSD	Sum of Infant Age disaggregates	119
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	17,091
TX_CURR_DSD	Age/Sex: 15-19 Male	965
TX_CURR_DSD	Age/Sex: 15-19 Female	1,215
TX_CURR_DSD	Sum of age/sex disaggregates	2,180
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	602
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,539
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	788
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,162
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,390
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	15,701
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	17,091
TX_CURR_DSD	Age/Sex: <1	110
TX_CURR_DSD	Age/Sex: <1-9	564
TX_CURR_DSD	Age/Sex: 10-14 Male	432
TX_CURR_DSD	Age/Sex: 10-14 Female	568
TX_CURR_DSD	Age/Sex: 20-24 Male	2,468
TX_CURR_DSD	Age/Sex: 25-49 Male	1,973
TX_CURR_DSD	Age/Sex: 50+ Male	508



TX_CURR_DSD	Age/Sex: 20-24 Female	4,695
TX_CURR_DSD	Age/Sex: 25-49 Female	2,976
TX_CURR_DSD	Age/Sex: 50+ Female	617
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,304
TX_NEW_DSD	By Age/Sex: <1	6
TX_NEW_DSD	By Age/Sex: 1-9	80
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	93
TX_NEW_DSD	By Age/Sex: 20-24 Male	98
TX_NEW_DSD	By Age/Sex: 25-49 Male	686
TX_NEW_DSD	By Age/Sex: 50+ Male	39
TX_NEW_DSD	By Age/Sex: 10-14 Female	56
TX_NEW_DSD	By Age/Sex: 15-19 Female	99
TX_NEW_DSD	By Age/Sex: 20-24 Female	153
TX_NEW_DSD	By Age/Sex: 25-49 Female	893
TX_NEW_DSD	By Age/Sex: 50+ Female	54
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,218
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	96
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	906
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	114
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,188
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,304
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	569
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	580
TX_PVLS_DSD	Numerator: Indication: Routine	55
TX_PVLS_DSD	Numerator: Indication: Targeted	514
TX_PVLS_DSD	Denominator: Indication: Routine	55



TX_PVLS_DSD	Denominator: Indication: Targeted	525
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	21
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	222
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	37
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	289
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	21
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	226
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	36
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	297
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,082
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,083
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	191
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	152
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and	46



	children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	317
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	253
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	10



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	191
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	318
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	252



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	385
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	634
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	386
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	635



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 13580	Mechanism Name: CIDRZ Achieve
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 19,032,193	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 19,032,193	
Funding Source	Funding Amount
GHP-State	19,032,193

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13580		
Mechanism Name:	CIDRZ Achieve		
Prime Partner Name:	CENTER FOR INFECTIOUS DISEASE AND RESEARCH IN ZAMBIA		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,800,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,075,697	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	9,406,496	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	900,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	140,878



	their results)	
PMTCT_ART_DSD	New on ART	9,411
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	7,334
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	140,878
PMTCT_STAT_DSD	Number of new ANC and L&D clients	140,876
PMTCT_STAT_DSD	By: Known positives at entry	6,755
PMTCT_STAT_DSD	By: Number of new positives identified	7,369
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	14,124
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	1,019
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	2,320
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	928
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	2,128
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	35
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	25,673
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	41,530
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	73,589
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	51
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	3,693



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	4,031
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	25,708
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	41,530
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	73,640
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	20,153
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	4,450
VMMC_CIRC_DSD	By Age: 15-19	7,076
VMMC_CIRC_DSD	By Age: 20-24	3,969
VMMC_CIRC_DSD	By Age: 25-29	2,633
VMMC_CIRC_DSD	By Age: 30-49	1,969
VMMC_CIRC_DSD	By Age: 50+	56
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	15,551
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	20,153
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	20,153
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
PP_PREV_DSD	Total number of people in the target population	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	0



	standards required	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	118,646
HTC_TST_DSD	Age/sex: 10-14 Male	1,806
HTC_TST_DSD	Age/sex: 15-19 Male	7,942
HTC_TST_DSD	Age/sex: 20-24 Male	13,526
HTC_TST_DSD	Age/sex: 25-49 Male	24,857
HTC_TST_DSD	Age/sex: 50+ Male	2,909
HTC_TST_DSD	Age/sex: 10-14 Female	1,581
HTC_TST_DSD	Age/sex: 15-19 Female	9,113
HTC_TST_DSD	Age/sex: 20-24 Female	17,229
HTC_TST_DSD	Age/sex: 25-49 Female	28,472
HTC_TST_DSD	Age/sex: 50+ Female	2,823
HTC_TST_DSD	Sum of Age/Sex disaggregates	110,258
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	424
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	342
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,197
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	3,003
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	277
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	239
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	667
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,768
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,002
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	225
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,012
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	49,238
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,755
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	57,641



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	11,767
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	106,879
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	118,646
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	719
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,811
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	487
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,673
HTC_TST_DSD	Test Result by Age: Positive: <1	130
HTC_TST_DSD	Test Result by Age: Positive: 1-9	415
HTC_TST_DSD	Age/sex: <1	2,338
HTC_TST_DSD	Age/sex: 1-9	6,038
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	24
HTC_TST_DSD	Service Delivery Point (Facility): VCT	118,622
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10,107
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	10,107
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	251
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,519
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	189
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,148
GEND_GBV_DSD	Number of people receiving post-GBV care	0



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,494
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,494
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	126
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,504
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	84
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,780
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	126,263
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,785
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	70,300
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,659
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	49,519
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	0
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	11,387
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	12,808
PMTCT_EID_DSD	Sum of Infant Age disaggregates	24,195
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	209,615
TX_CURR_DSD	Age/Sex: 15-19 Male	1,276
TX_CURR_DSD	Age/Sex: 15-19 Female	4,412
TX_CURR_DSD	Sum of age/sex disaggregates	5,688
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9,766
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	67,323
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	10,870
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	121,385
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	20,636
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	188,708
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	209,344
TX_CURR_DSD	Age/Sex: <1	1,864
TX_CURR_DSD	Age/Sex: <1-9	12,697
TX_CURR_DSD	Age/Sex: 10-14 Male	2,935
TX_CURR_DSD	Age/Sex: 10-14 Female	3,169
TX_CURR_DSD	Age/Sex: 20-24 Male	3,954
TX_CURR_DSD	Age/Sex: 25-49 Male	56,325
TX_CURR_DSD	Age/Sex: 50+ Male	5,768
TX_CURR_DSD	Age/Sex: 20-24 Female	15,572
TX_CURR_DSD	Age/Sex: 25-49 Female	93,536
TX_CURR_DSD	Age/Sex: 50+ Female	8,107
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	45,106



TX_NEW_DSD	By Age/Sex: <1	379
TX_NEW_DSD	By Age/Sex: 1-9	2,726
TX_NEW_DSD	By Age/Sex: 10-14 Male	700
TX_NEW_DSD	By Age/Sex: 15-19 Male	262
TX_NEW_DSD	By Age/Sex: 20-24 Male	844
TX_NEW_DSD	By Age/Sex: 25-49 Male	12,428
TX_NEW_DSD	By Age/Sex: 50+ Male	1,243
TX_NEW_DSD	By Age/Sex: 10-14 Female	677
TX_NEW_DSD	By Age/Sex: 15-19 Female	949
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,375
TX_NEW_DSD	By Age/Sex: 25-49 Female	19,772
TX_NEW_DSD	By Age/Sex: 50+ Female	1,751
TX_NEW_DSD	Sum of Age/Sex disaggregates	42,001
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,156
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,996
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,326
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	25,628
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	45,106
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	50,216
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	50,216
TX_PVLS_DSD	Numerator: Indication: Routine	37,642
TX_PVLS_DSD	Numerator: Indication: Targeted	12,574
TX_PVLS_DSD	Denominator: Indication: Routine	37,642
TX_PVLS_DSD	Denominator: Indication: Targeted	12,574
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	950
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	28,531
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	569



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	20,166
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	950
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	28,531
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	569
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	20,166
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	30,212
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,212
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	234
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,800
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	522
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	169
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	558
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,184
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	821
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	440



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	625
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,250
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,445
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,164
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	234
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,800
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	522
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	169
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	558



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,184
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	821
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	440
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	625
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,250
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,445
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	1,164



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,472
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,732
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,524
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,484
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,472
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,732
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,524
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,484

Implementing Mechanism Details



Mechanism ID: 13684	Mechanism Name: UNZA ZEPACT
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13684		
Mechanism Name:	UNZA ZEPACT		
Prime Partner Name:	University of Zambia School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13731	Mechanism Name: DAPP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People Humana Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13731		
Mechanism Name:	DAPP		
Prime Partner Name:	Development Aid from People to People Humana Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	86,969
PP_PREV_DSD	Total number of people in the target population	248,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	8,876
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	35,302
PP_PREV_DSD	Aggregated Age/sex: <15 Female	7,984
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	34,807



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	156
KP_PREV_DSD	Total estimated number of key population in the catchment area	300
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	29
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	27
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	55
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	45
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	200
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,236
HTC_TST_DSD	Age/sex: 10-14 Male	2,393



HTC_TST_DSD	Age/sex: 15-19 Male	3,609
HTC_TST_DSD	Age/sex: 20-24 Male	2,326
HTC_TST_DSD	Age/sex: 25-49 Male	3,718
HTC_TST_DSD	Age/sex: 50+ Male	1,391
HTC_TST_DSD	Age/sex: 10-14 Female	2,373
HTC_TST_DSD	Age/sex: 15-19 Female	3,981
HTC_TST_DSD	Age/sex: 20-24 Female	2,659
HTC_TST_DSD	Age/sex: 25-49 Female	4,056
HTC_TST_DSD	Age/sex: 50+ Female	1,587
HTC_TST_DSD	Sum of Age/Sex disaggregates	28,093
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	239
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	361
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	233
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	372
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	138
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	238
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	398
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	266
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	406
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	159
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,462
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,044
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,447
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,283
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,909
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,327
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	28,236
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	246



	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,131
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	245
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,202
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	14
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	143
HTC_TST_DSD	Service Delivery Point (Facility): VCT	28,236

Implementing Mechanism Details

Mechanism ID: 13787	Mechanism Name: CHAZ
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Churches Health Association of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13787			
Mechanism Name: CHAZ			
Prime Partner Name: Churches Health Association of Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,324
PMTCT_ART_DSD	New on ART	128
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	225
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,324
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,324
PMTCT_STAT_DSD	By: Known positives at entry	405
PMTCT_STAT_DSD	By: Number of new positives identified	355
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	760
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	31
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	95
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	32



PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	122
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	180
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	992
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	2,038
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	2,775
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	339
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	194
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	51
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	157
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	67
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	180
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	992
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	2,038
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	2,775
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	339
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	3,922
VMMC_CIRC_DSD	By Age: 0-60 days	15
VMMC_CIRC_DSD	By Age: 2 months - 9 years	44
VMMC_CIRC_DSD	By Age: 10-14	823
VMMC_CIRC_DSD	By Age: 15-19	1,280
VMMC_CIRC_DSD	By Age: 20-24	947



VMMC_CIRC_DSD	By Age: 25-29	516
VMMC_CIRC_DSD	By Age: 30-49	266
VMMC_CIRC_DSD	By Age: 50+	31
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,081
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	3,863
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	3,922
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	53,374
PP_PREV_DSD	Total number of people in the target population	53,374
PP_PREV_DSD	Aggregated Age/sex: <15 Male	6,696
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	15,927
PP_PREV_DSD	Aggregated Age/sex: <15 Female	9,273
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	21,478
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,858
KP_PREV_DSD	Total estimated number of key population in the catchment area	1,858
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	0



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,858
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are sex	0



	workers (Denominator: Total estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,858
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,724
HTC_TST_DSD	Age/sex: 10-14 Male	1,305
HTC_TST_DSD	Age/sex: 15-19 Male	1,615
HTC_TST_DSD	Age/sex: 20-24 Male	2,449
HTC_TST_DSD	Age/sex: 25-49 Male	3,377
HTC_TST_DSD	Age/sex: 50+ Male	1,072
HTC_TST_DSD	Age/sex: 10-14 Female	355
HTC_TST_DSD	Age/sex: 15-19 Female	1,976
HTC_TST_DSD	Age/sex: 20-24 Female	2,974
HTC_TST_DSD	Age/sex: 25-49 Female	3,415
HTC_TST_DSD	Age/sex: 50+ Female	1,154
HTC_TST_DSD	Sum of Age/Sex disaggregates	19,692
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	44
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	190
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	285



HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	373
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	306
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	216
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	252
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	444
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	283
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,907
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,363
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,205
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,249
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,112
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,612
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,724
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	55
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,199
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	485
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,282
HTC_TST_DSD	Test Result by Age: Positive: <1	24
HTC_TST_DSD	Test Result by Age: Positive: 1-9	264
HTC_TST_DSD	Age/sex: <1	207
HTC_TST_DSD	Age/sex: 1-9	825
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	9,012
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	3,166
HTC_TST_DSD	Service Delivery Point (Facility): VCT	4,514



HTC_TST_DSD	Service Delivery Point (Facility): VMMC	1,163
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,833
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	36
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	548
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	548
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	260
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	267
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	529
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	529
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	243
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	11



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	261
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	26,047
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	435
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	10,704
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	764
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	14,144
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	26,047
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	26,047
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	28,152
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	153
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	165
PMTCT_EID_DSD	Sum of Infant Age disaggregates	318
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	41,456
TX_CURR_DSD	Age/Sex: 15-19 Male	3,914
TX_CURR_DSD	Age/Sex: 15-19 Female	3,796
TX_CURR_DSD	Sum of age/sex disaggregates	7,710
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,419
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	17,174



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,723
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	19,140
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,142
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	36,314
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	41,456
TX_CURR_DSD	Age/Sex: <1	31
TX_CURR_DSD	Age/Sex: <1-9	98
TX_CURR_DSD	Age/Sex: 10-14 Male	2,176
TX_CURR_DSD	Age/Sex: 10-14 Female	2,541
TX_CURR_DSD	Age/Sex: 20-24 Male	3,576
TX_CURR_DSD	Age/Sex: 25-49 Male	7,312
TX_CURR_DSD	Age/Sex: 50+ Male	3,260
TX_CURR_DSD	Age/Sex: 20-24 Female	4,408
TX_CURR_DSD	Age/Sex: 25-49 Female	6,096
TX_CURR_DSD	Age/Sex: 50+ Female	4,248
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,026
TX_NEW_DSD	By Age/Sex: <1	69
TX_NEW_DSD	By Age/Sex: 1-9	219
TX_NEW_DSD	By Age/Sex: 10-14 Male	135
TX_NEW_DSD	By Age/Sex: 15-19 Male	681
TX_NEW_DSD	By Age/Sex: 20-24 Male	873
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,053
TX_NEW_DSD	By Age/Sex: 50+ Male	95
TX_NEW_DSD	By Age/Sex: 10-14 Female	150
TX_NEW_DSD	By Age/Sex: 15-19 Female	647
TX_NEW_DSD	By Age/Sex: 20-24 Female	818
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,132
TX_NEW_DSD	By Age/Sex: 50+ Female	154
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,738
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	234
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,717



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	227
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,848
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,026
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,518
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,239
TX_PVLS_DSD	Numerator: Indication: Targeted	2,518
TX_PVLS_DSD	Denominator: Indication: Targeted	2,239
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	136
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,078
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	154
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,150
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	122
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	958
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	138
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,021
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,005
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,005
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	213



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	324
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,001
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,079
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	341
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	184
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	314
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	991
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,152
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	350
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	32



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	213
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	324
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,001
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,079
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	341
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	184
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	314



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	991
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,152
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	350
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	337
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,662
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,679
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	337
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	2,662



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	327
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,679

Implementing Mechanism Details

Mechanism ID: 14339	Mechanism Name: PEPFAR Prevention Small Grants
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14339			
Mechanism Name: PEPFAR Prevention Small Grants			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,000
PP_PREV_DSD	Total number of people in the target population	4,420,493
PP_PREV_DSD	Aggregated Age/sex: <15 Male	2,950
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,850
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,000
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,200

Implementing Mechanism Details

Mechanism ID: 14420	Mechanism Name: LPHO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Lusaka Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 7,983,917	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,983,917	
Funding Source	Funding Amount
GHP-State	7,983,917

Cross-Cutting Budget Attribution(s)

Water	1,000
-------	-------

Budget Code Information

Mechanism ID:	14420		
Mechanism Name:	LPHO Follow On		
Prime Partner Name:	Lusaka Provincial Health Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	275,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	585,247	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	390,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	256,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,227,670	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	500,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,890
PMTCT_ART_DSD	New on ART	1,135



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,343
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,851
PMTCT_ART_TA	New on ART	401
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	461
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,890
PMTCT_STAT_DSD	Number of new ANC and L&D clients	28,890
PMTCT_STAT_DSD	By: Known positives at entry	2,006
PMTCT_STAT_DSD	By: Number of new positives identified	1,371
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,377
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	271
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	402
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	6,170
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	22,720
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	0



	50+	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,604
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,100
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	6,170
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	22,720
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,851
PMTCT_STAT_TA	Number of new ANC and L&D clients	23,851
PMTCT_STAT_TA	By: Known positives at entry	1,716
PMTCT_STAT_TA	By: Number of new positives identified	1,147
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,863
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	345
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	231



PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	0
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	4,758
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	19,093
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	1,368
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	919
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	4,758
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	19,093
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	15,888
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	1,734
VMMC_CIRC_DSD	By Age: 15-19	1,884
VMMC_CIRC_DSD	By Age: 20-24	3,398
VMMC_CIRC_DSD	By Age: 25-29	4,902
VMMC_CIRC_DSD	By Age: 30-49	2,375



VMMC_CIRC_DSD	By Age: 50+	1,595
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,611
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	15,888
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	15,888
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	78
PP_PREV_DSD	Total number of people in the target population	78
PP_PREV_DSD	Aggregated Age/sex: <15 Male	4
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	24
PP_PREV_DSD	Aggregated Age/sex: <15 Female	5
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	45
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,785
PP_PREV_TA	Total number of people in the target population	2,785
PP_PREV_TA	Aggregated Age/sex: <15 Male	193
PP_PREV_TA	Aggregated Age/sex: 15+ Male	969
PP_PREV_TA	Aggregated Age/sex: <15 Female	248
PP_PREV_TA	Aggregated Age/sex: 15+ Female	1,375
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,143
KP_PREV_DSD	Total estimated number of key population in the catchment area	2,143
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	305
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with	1,132



	individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	322
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	384
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	305
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,132
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	322
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	384
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,587
HTC_TST_DSD	Age/sex: 10-14 Male	910
HTC_TST_DSD	Age/sex: 15-19 Male	1,111
HTC_TST_DSD	Age/sex: 20-24 Male	1,113
HTC_TST_DSD	Age/sex: 25-49 Male	7,784
HTC_TST_DSD	Age/sex: 50+ Male	1,110
HTC_TST_DSD	Age/sex: 10-14 Female	1,362



HTC_TST_DSD	Age/sex: 15-19 Female	1,666
HTC_TST_DSD	Age/sex: 20-24 Female	1,669
HTC_TST_DSD	Age/sex: 25-49 Female	11,675
HTC_TST_DSD	Age/sex: 50+ Female	1,669
HTC_TST_DSD	Sum of Age/Sex disaggregates	30,069
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	35
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	132
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	132
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	933
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	132
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	54
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	202
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	202
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,401
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	202
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,548
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,118
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,242
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,679
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,790
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	27,797
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	31,587
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	62
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,329
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	87
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	2,007



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	16
HTC_TST_DSD	Test Result by Age: Positive: 1-9	44
HTC_TST_DSD	Age/sex: <1	381
HTC_TST_DSD	Age/sex: 1-9	1,137
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	6,316
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	18,952
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	46
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	6,273
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,945
HTC_TST_TA	Age/sex: 10-14 Male	833
HTC_TST_TA	Age/sex: 15-19 Male	1,022
HTC_TST_TA	Age/sex: 20-24 Male	1,026
HTC_TST_TA	Age/sex: 25-49 Male	7,133
HTC_TST_TA	Age/sex: 50+ Male	1,016
HTC_TST_TA	Age/sex: 10-14 Female	1,251
HTC_TST_TA	Age/sex: 15-19 Female	1,527
HTC_TST_TA	Age/sex: 20-24 Female	1,534
HTC_TST_TA	Age/sex: 25-49 Female	10,697
HTC_TST_TA	Age/sex: 50+ Female	1,527
HTC_TST_TA	Sum of Age/Sex disaggregates	27,566
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	30
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	122
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	122
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	856
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	123
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	49
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	188
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	188



HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	1,286
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	187
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,446
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,224
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,005
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,270
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,451
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	25,494
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	28,945
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	49
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,224
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	81
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,848
HTC_TST_TA	Test Result by Age: Positive: <1	13
HTC_TST_TA	Test Result by Age: Positive: 1-9	38
HTC_TST_TA	Age/sex: <1	350
HTC_TST_TA	Age/sex: 1-9	1,029
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	5,792
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	0
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	0
HTC_TST_TA	Service Delivery Point (Facility): VCT	17,365
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	5,788



HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,859
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,859
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	96
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	863
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	188
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,712
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	12
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	12
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,797
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,797
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	65
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	590
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	118
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,024
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	15
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	15
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	6



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	59,372
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,190
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	19,712
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,747
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	33,723
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	7,124
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,124
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	5,138
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,986
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	13,207
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	504
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	4,517
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	818
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	7,368
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	1,585
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent:	1,585



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,127
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	458
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	589
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	392
PMTCT_EID_DSD	Sum of Infant Age disaggregates	981
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	12
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	280
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	210
PMTCT_EID_TA	Sum of Infant Age disaggregates	490
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	75,014
TX_CURR_DSD	Age/Sex: 15-19 Male	223
TX_CURR_DSD	Age/Sex: 15-19 Female	518
TX_CURR_DSD	Sum of age/sex disaggregates	741
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,543
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,397
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	7,040



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,034
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,583
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	64,431
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	75,014
TX_CURR_DSD	Age/Sex: <1	1,484
TX_CURR_DSD	Age/Sex: <1-9	5,107
TX_CURR_DSD	Age/Sex: 10-14 Male	1,114
TX_CURR_DSD	Age/Sex: 10-14 Female	2,668
TX_CURR_DSD	Age/Sex: 20-24 Male	4,450
TX_CURR_DSD	Age/Sex: 25-49 Male	14,208
TX_CURR_DSD	Age/Sex: 50+ Male	1,113
TX_CURR_DSD	Age/Sex: 20-24 Female	10,379
TX_CURR_DSD	Age/Sex: 25-49 Female	31,158
TX_CURR_DSD	Age/Sex: 50+ Female	2,592
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,722
TX_CURR_TA	Age/Sex: 15-19 Male	57
TX_CURR_TA	Age/Sex: 15-19 Female	117
TX_CURR_TA	Sum of Age/Sex disaggregations	174
TX_CURR_TA	Aggregated Age/Sex: <15 Male	813
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,322
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,534
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	10,053
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,347
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	14,375
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	16,722
TX_CURR_TA	Age/Sex: <1	335
TX_CURR_TA	Age/Sex: 1-9	1,156
TX_CURR_TA	Age/Sex: 10-14 Male	254
TX_CURR_TA	Age/Sex: 10-14 Female	599
TX_CURR_TA	Age/Sex: 20-24 Male	1,004
TX_CURR_TA	Age/Sex: 25-49 Male	3,009



TX_CURR_TA	Age/Sex: 50+ Male	252
TX_CURR_TA	Age/Sex: 20-24 Female	2,331
TX_CURR_TA	Age/Sex: 25-49 Female	7,025
TX_CURR_TA	Age/Sex: 50+ Female	583
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	16,135
TX_NEW_DSD	By Age/Sex: <1	278
TX_NEW_DSD	By Age/Sex: 1-9	961
TX_NEW_DSD	By Age/Sex: 10-14 Male	208
TX_NEW_DSD	By Age/Sex: 15-19 Male	42
TX_NEW_DSD	By Age/Sex: 20-24 Male	831
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,898
TX_NEW_DSD	By Age/Sex: 50+ Male	207
TX_NEW_DSD	By Age/Sex: 10-14 Female	494
TX_NEW_DSD	By Age/Sex: 15-19 Female	96
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,941
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,694
TX_NEW_DSD	By Age/Sex: 50+ Female	485
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,896
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	672
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,978
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,269
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	9,216
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	16,135
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,613
TX_NEW_TA	By Age/Sex: 1-9	170
TX_NEW_TA	By Age/Sex: 10-14 Male	41
TX_NEW_TA	By Age/Sex: 15-19 Male	8
TX_NEW_TA	By Age/Sex: 20-24 Male	158
TX_NEW_TA	By Age/Sex: 25-49 Male	471
TX_NEW_TA	By Age/Sex: 50+ Male	36



TX_NEW_TA	By Age/Sex: 10-14 Female	106
TX_NEW_TA	By Age/Sex: 15-19 Female	18
TX_NEW_TA	By Age/Sex: 20-24 Female	367
TX_NEW_TA	By Age/Sex: 25-49 Female	1,096
TX_NEW_TA	By Age/Sex: 50+ Female	91
TX_NEW_TA	Sum of Age/Sex disaggregates	2,392
TX_NEW_TA	Aggregated Grouping by Age: <1	51
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	121
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	673
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	247
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,572
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,613
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,227
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	24,227
TX_PVLS_DSD	Numerator: Indication: Routine	19,380
TX_PVLS_DSD	Numerator: Indication: Targeted	4,847
TX_PVLS_DSD	Denominator: Indication: Routine	19,380
TX_PVLS_DSD	Denominator: Indication: Targeted	4,847
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,641
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	9,690
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,422
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,474
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,641
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,690
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,422
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,474
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	2,518



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,518
TX_PVLS_TA	Numerator: Indication: Routine	2,015
TX_PVLS_TA	Numerator: Indication: Targeted	503
TX_PVLS_TA	Denominator: Indication: Routine	2,015
TX_PVLS_TA	Denominator: Indication: Targeted	503
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	253
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,004
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	254
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	1,007
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	253
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,004
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	254
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	1,007
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,033
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,033
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	281
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	972
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	211
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	42



	months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	842
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,526
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	210
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	499
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	99
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,966
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,894
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	491
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	281
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	972



TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	211
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	842
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,526
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	210
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	499
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of	1,966



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,894
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	491
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	615
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,619
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,348
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,451
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	615
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	3,619

	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,348
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,451
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,220
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,220
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	83
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	221



TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	511
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	83
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	1



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	221
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	48
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	170
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	511



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	313
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	109
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	733
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	65
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	313
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total	733



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--

Implementing Mechanism Details

Mechanism ID: 14421	Mechanism Name: SPMO Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Southern Provincial Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,651,263	
Applied Pipeline Amount: 841,490	
Total All Funding Sources and Applied Pipeline Amount: 6,492,753	
Funding Source	Funding Amount
GHP-State	5,651,263

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14421		
Mechanism Name:	SPMO Follow On		
Prime Partner Name:	Southern Provincial Health Office		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	379,089	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	173,749	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	189,544	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	221,135	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	132,972	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	189,544	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	157,982	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	490,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,317,248	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	350,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	84,207
PMTCT_ART_DSD	New on ART	5,615
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,198
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,794
PMTCT_ART_TA	New on ART	285
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	164
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	84,207
PMTCT_STAT_DSD	Number of new ANC and L&D clients	84,207
PMTCT_STAT_DSD	By: Known positives at entry	5,685
PMTCT_STAT_DSD	By: Number of new positives identified	6,066
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	11,751
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	121
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	1,037
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	0
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	74
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	397



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	1,341
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	4,752
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	20,580
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	56,763
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	771
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	5,214
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	4,907
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	1,341
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	4,752
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	20,580
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	56,763
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	771
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,794
PMTCT_STAT_TA	Number of new ANC and L&D clients	6,794
PMTCT_STAT_TA	By: Known positives at entry	48
PMTCT_STAT_TA	By: Number of new positives identified	327
PMTCT_STAT_TA	Sum of Positives Status disaggregates	375
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	4



PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	12
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	6
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	147
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	23
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	2,157
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	4,612
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	2
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	33
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	173
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	18
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	2,155
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	4,618
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	3
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	9,883
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	424



VMMC_CIRC_DSD	By Age: 15-19	2,819
VMMC_CIRC_DSD	By Age: 20-24	2,416
VMMC_CIRC_DSD	By Age: 25-29	2,695
VMMC_CIRC_DSD	By Age: 30-49	1,406
VMMC_CIRC_DSD	By Age: 50+	123
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	5,782
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	9,883
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	9,883
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	104,815
PP_PREV_DSD	Total number of people in the target population	104,815
PP_PREV_DSD	Aggregated Age/sex: <15 Male	4,472
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	44,090
PP_PREV_DSD	Aggregated Age/sex: <15 Female	5,239
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	51,014
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,813
PP_PREV_TA	Total number of people in the target population	3,813
PP_PREV_TA	Aggregated Age/sex: <15 Male	188
PP_PREV_TA	Aggregated Age/sex: 15+ Male	1,626
PP_PREV_TA	Aggregated Age/sex: <15 Female	191
PP_PREV_TA	Aggregated Age/sex: 15+ Female	1,808
KP_PREV_TA	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,824



HTC_TST_DSD	Age/sex: 10-14 Male	1,074
HTC_TST_DSD	Age/sex: 15-19 Male	1,064
HTC_TST_DSD	Age/sex: 20-24 Male	2,660
HTC_TST_DSD	Age/sex: 25-49 Male	5,440
HTC_TST_DSD	Age/sex: 50+ Male	739
HTC_TST_DSD	Age/sex: 10-14 Female	1,357
HTC_TST_DSD	Age/sex: 15-19 Female	820
HTC_TST_DSD	Age/sex: 20-24 Female	3,431
HTC_TST_DSD	Age/sex: 25-49 Female	7,655
HTC_TST_DSD	Age/sex: 50+ Female	532
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,772
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	104
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	121
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	279
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	542
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	45
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	139
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	64
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	435
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	686
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	63
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,074
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,803
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,409
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	12,538
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,483
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	22,341
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	24,824



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	104
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	987
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	141
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,248
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2
HTC_TST_DSD	Age/sex: 1-9	52
HTC_TST_DSD	Service Delivery Point (Facility): VCT	24,124
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	321
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	127
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	252
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,688
HTC_TST_TA	Age/sex: 10-14 Male	118
HTC_TST_TA	Age/sex: 15-19 Male	111
HTC_TST_TA	Age/sex: 20-24 Male	406
HTC_TST_TA	Age/sex: 25-49 Male	563
HTC_TST_TA	Age/sex: 50+ Male	35
HTC_TST_TA	Age/sex: 10-14 Female	137
HTC_TST_TA	Age/sex: 15-19 Female	210
HTC_TST_TA	Age/sex: 20-24 Female	465
HTC_TST_TA	Age/sex: 25-49 Female	599
HTC_TST_TA	Age/sex: 50+ Female	32
HTC_TST_TA	Sum of Age/Sex disaggregates	2,676
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	9
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	13
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	44
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	43



HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	6
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	16
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	13
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	55
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	65
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	1
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	120
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,116
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	147
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,305
HTC_TST_TA	Sum of Aggregated Age/Sex <15	267
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	2,421
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,688
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	9
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	104
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	18
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	136
HTC_TST_TA	Test Result by Age: Positive: 1-9	2
HTC_TST_TA	Age/sex: 1-9	12
HTC_TST_TA	Service Delivery Point (Facility): VCT	2,616
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	72
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,068
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,068



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	515
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	29
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	499
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	463
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	463
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The	20



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	190
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	21
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	232
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	0



	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	44,456
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,125
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	18,698
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,444
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	21,189
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	673
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	673
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	673
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	716
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	36
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	311
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	36
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	333
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	72
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	72
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	72
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,885
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,083
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5,968
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	361
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	153
PMTCT_EID_TA	Sum of Infant Age disaggregates	514
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,593
TX_CURR_DSD	Age/Sex: 15-19 Male	620
TX_CURR_DSD	Age/Sex: 15-19 Female	668
TX_CURR_DSD	Sum of age/sex disaggregates	1,288
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,427
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,704
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,535
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	13,927
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,962
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	26,631
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	29,593
TX_CURR_DSD	Age/Sex: <1-9	216
TX_CURR_DSD	Age/Sex: 10-14 Male	1,381
TX_CURR_DSD	Age/Sex: 10-14 Female	1,365



TX_CURR_DSD	Age/Sex: 20-24 Male	4,069
TX_CURR_DSD	Age/Sex: 25-49 Male	7,363
TX_CURR_DSD	Age/Sex: 50+ Male	652
TX_CURR_DSD	Age/Sex: 20-24 Female	4,458
TX_CURR_DSD	Age/Sex: 25-49 Female	8,267
TX_CURR_DSD	Age/Sex: 50+ Female	534
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,771
TX_CURR_TA	Age/Sex: 15-19 Male	27
TX_CURR_TA	Age/Sex: 15-19 Female	23
TX_CURR_TA	Sum of Age/Sex disaggregations	50
TX_CURR_TA	Aggregated Age/Sex: <15 Male	83
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	784
TX_CURR_TA	Aggregated Age/Sex: <15 Female	90
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	814
TX_CURR_TA	Sum of Aggregated Age/Sex <15	173
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,598
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,771
TX_CURR_TA	Age/Sex: 1-9	10
TX_CURR_TA	Age/Sex: 10-14 Male	83
TX_CURR_TA	Age/Sex: 10-14 Female	80
TX_CURR_TA	Age/Sex: 20-24 Male	332
TX_CURR_TA	Age/Sex: 25-49 Male	394
TX_CURR_TA	Age/Sex: 50+ Male	31
TX_CURR_TA	Age/Sex: 20-24 Female	346
TX_CURR_TA	Age/Sex: 25-49 Female	405
TX_CURR_TA	Age/Sex: 50+ Female	40
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,087
TX_NEW_DSD	By Age/Sex: 1-9	13
TX_NEW_DSD	By Age/Sex: 10-14 Male	272
TX_NEW_DSD	By Age/Sex: 15-19 Male	105



TX_NEW_DSD	By Age/Sex: 20-24 Male	615
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,232
TX_NEW_DSD	By Age/Sex: 50+ Male	144
TX_NEW_DSD	By Age/Sex: 10-14 Female	256
TX_NEW_DSD	By Age/Sex: 15-19 Female	144
TX_NEW_DSD	By Age/Sex: 20-24 Female	787
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,338
TX_NEW_DSD	By Age/Sex: 50+ Female	181
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,074
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	273
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,096
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	268
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,450
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,087
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	158
TX_NEW_TA	By Age/Sex: 1-9	2
TX_NEW_TA	By Age/Sex: 10-14 Male	10
TX_NEW_TA	By Age/Sex: 15-19 Male	6
TX_NEW_TA	By Age/Sex: 20-24 Male	21
TX_NEW_TA	By Age/Sex: 25-49 Male	34
TX_NEW_TA	By Age/Sex: 50+ Male	9
TX_NEW_TA	By Age/Sex: 10-14 Female	6
TX_NEW_TA	By Age/Sex: 15-19 Female	11
TX_NEW_TA	By Age/Sex: 20-24 Female	23
TX_NEW_TA	By Age/Sex: 25-49 Female	26
TX_NEW_TA	By Age/Sex: 50+ Female	10
TX_NEW_TA	Sum of Age/Sex disaggregates	156
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	10
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	70
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	8
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	70



TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	158
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,804
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,804
TX_PVLS_DSD	Numerator: Indication: Routine	10,804
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Indication: Routine	10,804
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	485
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	4,657
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	511
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	5,151
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	485
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	4,657
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	511
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	5,151
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	487
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	487
TX_PVLS_TA	Numerator: Indication: Routine	487
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	487
TX_PVLS_TA	Denominator: Indication: Targeted	0
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	23
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	219



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	26
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	219
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	23
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	219
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	26
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	219
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,280
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,280
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	237
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	609
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,284
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	205
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	266
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults	150



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	704
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,569
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	139
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	237
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	107
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	609
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,284



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	205
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	266
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	704
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,569
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	139
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	238
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	2,205



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	275
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,562
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	238
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,205
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	275
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,562
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	129
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	129
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and	1



	children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	30
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	1



	have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	3



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	58



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58

Implementing Mechanism Details

Mechanism ID: 14452	Mechanism Name: Society for Family Health
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	Funding Amount
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	14452		
Mechanism Name:	Society for Family Health		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	20,154
VMMC_CIRC_DSD	By Age: 10-14	2,822
VMMC_CIRC_DSD	By Age: 15-19	3,023
VMMC_CIRC_DSD	By Age: 20-24	6,046
VMMC_CIRC_DSD	By Age: 25-29	6,046
VMMC_CIRC_DSD	By Age: 30-49	2,015
VMMC_CIRC_DSD	By Age: 50+	202
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	12,093
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	20,154
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	20,154
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,000
PP_PREV_DSD	Total number of people in the target population	120,000
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,400
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	21,600



PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,000
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,000

Implementing Mechanism Details

Mechanism ID: 14507		Mechanism Name: Family Health International	
Funding Agency: DOD		Procurement Type: Grant	
Prime Partner Name: FHI 360			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 5,142,304	
Applied Pipeline Amount: 1,512,399	
Total All Funding Sources and Applied Pipeline Amount: 6,654,703	
Funding Source	Funding Amount
GHP-State	5,142,304

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
Motor Vehicles: Purchased	575,000

Budget Code Information

Mechanism ID: 14507			
Mechanism Name: Family Health International			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	40,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	287,601	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,030,191	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	634,512	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,606
PMTCT_ART_TA	New on ART	660
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,140
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,606



PMTCT_STAT_TA	Number of new ANC and L&D clients	7,935
PMTCT_STAT_TA	By: Known positives at entry	1,800
PMTCT_STAT_TA	By: Number of new positives identified	660
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,460
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	35,900
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,539
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,431
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,000
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,930
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,539
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	33,361
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	35,900
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	260
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,404
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	310
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,018
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	718
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	1,436
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	1,436
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	7,180
HTC_TST_TA	Service Delivery Point (Facility): VCT	14,360
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	5,744
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	718



HTC_TST_TA	Service Delivery Point (Facility): Index testing	4,308
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	430
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	430
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	251
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	153
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	183
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	183
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	96
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1

TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	85
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	33,562
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	564
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	14,219
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	638
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	18,141
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	183
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	183
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	73
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	110
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	332
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	1,000
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,332
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	2
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	69
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	43,752
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,539
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	17,362
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,493



TX_CURR_TA	Aggregated Age/Sex: 15+ Female	23,358
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,032
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	40,720
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	43,752
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,293
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	234
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,164
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	279
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,616
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	6,293
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,488
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,488
TX_PVLS_TA	Numerator: Indication: Routine	2,098
TX_PVLS_TA	Numerator: Indication: Targeted	8,390
TX_PVLS_TA	Denominator: Indication: Routine	2,098
TX_PVLS_TA	Denominator: Indication: Targeted	8,390
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	1,139
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	3,505
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,093
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	4,751
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	1,139
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,505
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,093
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	4,751
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,499
TX_RET_TA	Total number of adults and children who initiated ART	3,499



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	276
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,084
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	328
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,811
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	276
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,084
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	328
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,811



Implementing Mechanism Details

Mechanism ID: 16634	Mechanism Name: USAID/Copperbelt Lusaka Zambia Family activity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Expanded Church Response Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,729,504	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,729,504	
Funding Source	Funding Amount
GHP-State	4,729,504

Cross-Cutting Budget Attribution(s)

Economic Strengthening	130,000
Education	200,000

Budget Code Information

Mechanism ID:	16634		
Mechanism Name:	USAID/Copperbelt Lusaka Zambia Family activity		
Prime Partner Name:	Expanded Church Response Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,379,504	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	18,107
PP_PREV_DSD	Total number of people in the target population	18,107
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	9,053
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	9,054
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	100,000
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	2,700
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	6,354



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	2,700
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	6,353
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	271
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	11,099
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	5,956
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	7,851



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	18,107
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	5,956
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	7,851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	7,851
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,107
OVC_SERV_TA	Age/Sex: 18+ Male	0
OVC_SERV_TA	Age/Sex: 18+ Female	0
OVC_SERV_TA	Sum of Age/Sex disaggregates	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	181
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	7,424
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	5,251
OVC_SERV_TA	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	5,251

Implementing Mechanism Details

Mechanism ID: 16656	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16690	Mechanism Name: SAVVY
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 900,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 900,000	
Funding Source	Funding Amount
GHP-State	900,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16690			
Mechanism Name: SAVVY			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	900,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16833	Mechanism Name: Human Resource Information System (HRIS)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	20,000
----------------------------	--------

Budget Code Information

Mechanism ID:	16833		
Mechanism Name:	Human Resource Information System (HRIS)		
Prime Partner Name:	Emory University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17100	Mechanism Name: Stamping Out and Preventing Gender-Based Violence (STOP GBV) :
----------------------------	---

Approved



	Prevention & Advocacy
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Zambia Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,307,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,307,000	
Funding Source	Funding Amount
GHP-State	1,307,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	1,307,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17100		
Mechanism Name:	Stamping Out and Preventing Gender-Based Violence (STOP GBV) :		
Prime Partner Name:	Prevention & Advocacy Zambia Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	607,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	150,000
PP_PREV_DSD	Total number of people in the target population	6,053,299
PP_PREV_DSD	Aggregated Age/sex: <15 Male	8,248
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	53,462
PP_PREV_DSD	Aggregated Age/sex: <15 Female	9,923
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	78,367
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,900
OVC_SERV_DSD	Age/Sex: 18+ Male	1,766
OVC_SERV_DSD	Age/Sex: 18+ Female	2,520
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,286
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	742



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	5,404
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	556
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	2,887
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	742
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	556
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,546
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	868
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,347
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,293
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	0

Implementing Mechanism Details

Mechanism ID: 17168	Mechanism Name: Zambian OVC Management Information Systems (ZOMIS) / Data Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Expanded Church Response Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17168			
Mechanism Name: Zambian OVC Management Information Systems (ZOMIS) / Data Rising			
Prime Partner Name: Expanded Church Response Trust			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17354	Mechanism Name: Livelihoods and Food Security Technical Assistance (LIFT) II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	Funding Amount
GHP-State	600,000

Cross-Cutting Budget Attribution(s)



Food and Nutrition: Policy, Tools, and Service Delivery	600,000
---	---------

Budget Code Information

Mechanism ID:	17354		
Mechanism Name:	Livelihoods and Food Security Technical Assistance (LIFT) II		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,000
OVC_SERV_DSD	Age/Sex: 18+ Male	214
OVC_SERV_DSD	Age/Sex: 18+ Female	218
OVC_SERV_DSD	Sum of Age/Sex disaggregates	432
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	325
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	325
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,000
OVC_SERV_TA	Age/Sex: 18+ Male	70
OVC_SERV_TA	Age/Sex: 18+ Female	280



OVC_SERV_TA	Sum of Age/Sex disaggregates	350
-------------	------------------------------	-----

Implementing Mechanism Details

Mechanism ID: 17355	Mechanism Name: Applying Science to Strengthen & Improve Systems Project (ASSIST)/USAID Healthcare Improvement Project (HCI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: (ASSIST) - Applying Science to Strengthen and Improve Systems Project	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17355		
Mechanism Name:	Applying Science to Strengthen & Improve Systems Project (ASSIST)/USAID Healthcare Improvement Project (HCI)		
Prime Partner Name:	(ASSIST) - Applying Science to Strengthen and Improve Systems Project		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17356	Mechanism Name: Food and Nutrition Technical Assistance (FANTA III)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 441,775	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 441,775	
Funding Source	Funding Amount
GHP-State	441,775

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	441,775
---	---------

Budget Code Information

Mechanism ID: 17356



Mechanism Name:	Food and Nutrition Technical Assistance (FANTA III)		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	441,775	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,882
OVC_SERV_DSD	Age/Sex: 18+ Male	653
OVC_SERV_DSD	Age/Sex: 18+ Female	712
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,365
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	728
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	789

Implementing Mechanism Details

Mechanism ID: 17360	Mechanism Name: Time To Learn
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Education Development Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17360			
Mechanism Name: Time To Learn			
Prime Partner Name: Education Development Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17395	Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Luapula Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17395			
Mechanism Name: District OVC Systems Strengthening (DOSS) / Community Rising			
Prime Partner Name: Luapula Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17396	Mechanism Name: Sexual and Reproductive Health for All Initiative (SARAI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 920,000	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 920,000	
Funding Source	Funding Amount
GHP-State	920,000

Cross-Cutting Budget Attribution(s)

Condom programming	275,000
--------------------	---------

Budget Code Information

Mechanism ID:	17396		
Mechanism Name:	Sexual and Reproductive Health for All Initiative (SARAI)		
Prime Partner Name:	Society for Family Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	370,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	47,346



PP_PREV_DSD	Total number of people in the target population	518,135
PP_PREV_DSD	Aggregated Age/sex: <15 Male	11,834
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	11,838
PP_PREV_DSD	Aggregated Age/sex: <15 Female	11,834
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	11,840
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,600
OVC_SERV_DSD	Age/Sex: 18+ Male	825
OVC_SERV_DSD	Age/Sex: 18+ Female	825
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,650
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,475
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,475

Implementing Mechanism Details

Mechanism ID: 17399	Mechanism Name: USAID/District Coverage of Health Services (DISCOVER-H)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 10,352,512	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,352,512	
Funding Source	Funding Amount
GHP-State	10,352,512

Cross-Cutting Budget Attribution(s)

Water	50,000
-------	--------



Budget Code Information

Mechanism ID: 17399			
Mechanism Name: USAID/District Coverage of Health Services (DISCOVER-H)			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	784,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	198,546	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,023,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,523,992	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,239,100	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,250,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	232,974	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,208
PMTCT_ART_DSD	New on ART	861
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	90
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,208
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,189
PMTCT_STAT_DSD	By: Known positives at entry	143
PMTCT_STAT_DSD	By: Number of new positives identified	1,327
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,470
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	105
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	29
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	29
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	11
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	950



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	261
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	261
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	760
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	143
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	84
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	16
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	115
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	33
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	33
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	91
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	17
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	74,199
VMMC_CIRC_DSD	By Age: 0-60 days	1,483
VMMC_CIRC_DSD	By Age: 10-14	18,552
VMMC_CIRC_DSD	By Age: 15-19	18,552
VMMC_CIRC_DSD	By Age: 20-24	14,840
VMMC_CIRC_DSD	By Age: 25-29	14,841
VMMC_CIRC_DSD	By Age: 30-49	5,195
VMMC_CIRC_DSD	By Age: 50+	742
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	52,686
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	72,722



VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	74,199
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	200,000
PP_PREV_DSD	Total number of people in the target population	1,277,945
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	105,295
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	94,705
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	152,000
HTC_TST_DSD	Age/sex: 10-14 Male	2,412
HTC_TST_DSD	Age/sex: 15-19 Male	2,136
HTC_TST_DSD	Age/sex: 20-24 Male	1,928
HTC_TST_DSD	Age/sex: 25-49 Male	5,348
HTC_TST_DSD	Age/sex: 50+ Male	1,407
HTC_TST_DSD	Age/sex: 10-14 Female	2,411
HTC_TST_DSD	Age/sex: 15-19 Female	2,135
HTC_TST_DSD	Age/sex: 20-24 Female	1,930
HTC_TST_DSD	Age/sex: 25-49 Female	5,343
HTC_TST_DSD	Age/sex: 50+ Female	1,420
HTC_TST_DSD	Sum of Age/Sex disaggregates	26,470
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	313
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	278
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	251
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	696
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	183
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	313
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	278
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	251
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	695

HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	184
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	33,179
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	42,029
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	33,076
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	43,716
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	66,255
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	85,745
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	152,000
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	4,313
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,261
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	4,298
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,681
HTC_TST_DSD	Test Result by Age: Positive: <1	202
HTC_TST_DSD	Test Result by Age: Positive: 1-9	1,426
HTC_TST_DSD	Age/sex: <1	1,560
HTC_TST_DSD	Age/sex: 1-9	10,970
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	103,117
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	41,300
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	7,583
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	20,640
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4,505
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	5,706
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,492



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	5,937
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,398
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,298
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,298
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	857
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	94
PMTCT_EID_DSD	Sum of Infant Age disaggregates	951
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,092
TX_CURR_DSD	Age/Sex: 15-19 Male	385
TX_CURR_DSD	Age/Sex: 15-19 Female	385
TX_CURR_DSD	Sum of age/sex disaggregates	770
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,573
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,534
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,580
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,404
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,153
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,938
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	26,091
TX_CURR_DSD	Age/Sex: <1	282
TX_CURR_DSD	Age/Sex: <1-9	1,979
TX_CURR_DSD	Age/Sex: 10-14 Male	434
TX_CURR_DSD	Age/Sex: 10-14 Female	434
TX_CURR_DSD	Age/Sex: 20-24 Male	344
TX_CURR_DSD	Age/Sex: 25-49 Male	1,031



TX_CURR_DSD	Age/Sex: 50+ Male	256
TX_CURR_DSD	Age/Sex: 20-24 Female	351
TX_CURR_DSD	Age/Sex: 25-49 Female	1,189
TX_CURR_DSD	Age/Sex: 50+ Female	256
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,590
TX_NEW_DSD	By Age/Sex: <1	202
TX_NEW_DSD	By Age/Sex: 1-9	1,428
TX_NEW_DSD	By Age/Sex: 10-14 Male	313
TX_NEW_DSD	By Age/Sex: 15-19 Male	278
TX_NEW_DSD	By Age/Sex: 20-24 Male	250
TX_NEW_DSD	By Age/Sex: 25-49 Male	695
TX_NEW_DSD	By Age/Sex: 50+ Male	184
TX_NEW_DSD	By Age/Sex: 10-14 Female	313
TX_NEW_DSD	By Age/Sex: 15-19 Female	278
TX_NEW_DSD	By Age/Sex: 20-24 Female	250
TX_NEW_DSD	By Age/Sex: 25-49 Female	695
TX_NEW_DSD	By Age/Sex: 50+ Female	184
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,440
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	4,059
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,141
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,045
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,345
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	18,590
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,076
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	32,299
TX_PVLS_DSD	Numerator: Indication: Routine	8,076
TX_PVLS_DSD	Denominator: Indication: Routine	32,299



TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,778
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,219
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,779
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,300
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	7,052
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	8,931
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	7,028
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,288
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,273
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,090
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	482
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	234
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12	62



	months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	87
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	234
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	63
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	544
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	119
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	106



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	264
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	118
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	105
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	98
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	266



TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,367
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,737
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,365
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,804
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,937
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,455
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,930
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	2,553



	including those who have died, those who have stopped ART, and those lost to follow-up)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 17400	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17403	Mechanism Name: Gender Based Violence - Survivor Support Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Vision International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
G2G: No	Managing Agency:	

Total All Funding Sources: 2,184,810	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,184,810	
Funding Source	Funding Amount
GHP-State	2,184,810

Cross-Cutting Budget Attribution(s)

Gender: GBV	2,184,810
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation



Budget Code Information

Mechanism ID: 17403			
Mechanism Name: Gender Based Violence - Survivor Support Project			
Prime Partner Name: World Vision International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	111,610	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	573,200	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	15,726
PP_PREV_DSD	Total number of people in the target population	15,726
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,742
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	9,984
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	0



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,562
HTC_TST_DSD	Age/sex: 10-14 Male	1
HTC_TST_DSD	Age/sex: 15-19 Male	5
HTC_TST_DSD	Age/sex: 20-24 Male	13
HTC_TST_DSD	Age/sex: 25-49 Male	95
HTC_TST_DSD	Age/sex: 50+ Male	13
HTC_TST_DSD	Age/sex: 10-14 Female	2
HTC_TST_DSD	Age/sex: 15-19 Female	8
HTC_TST_DSD	Age/sex: 20-24 Female	25
HTC_TST_DSD	Age/sex: 25-49 Female	77
HTC_TST_DSD	Age/sex: 50+ Female	7
HTC_TST_DSD	Sum of Age/Sex disaggregates	246
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	1
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	132
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	610
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	345
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,474
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	477



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,084
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,561
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	58
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	17
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	131
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	6
HTC_TST_DSD	Age/sex: <1	2
HTC_TST_DSD	Age/sex: 1-9	11
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,561
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
GEND_GBV_DSD	Number of people receiving post-GBV care	15,651
GEND_GBV_DSD	Age/Sex: <10 Male	885
GEND_GBV_DSD	Age/Sex: 10-14 Male	347
GEND_GBV_DSD	Age/Sex: 20-24 Male	273
GEND_GBV_DSD	Age/Sex: 25-49 Male	1,184
GEND_GBV_DSD	Age/Sex: 50+ Male	101
GEND_GBV_DSD	Age/Sex: <10 Female	1,188
GEND_GBV_DSD	Age/Sex: 10-14 Female	1,007
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,963
GEND_GBV_DSD	Age/Sex: 25-49 Female	5,123
GEND_GBV_DSD	Age/Sex: 50+ Female	231
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	3,427
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	13,931
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,720
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	688



GEND_GBV_DSD	Age/Sex: 15-19 Female	2,819
GEND_GBV_DSD	Age/Sex: 15-19 male	531
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,757
OVC_SERV_DSD	Age/Sex: 18+ Male	4,292
OVC_SERV_DSD	Age/Sex: 18+ Female	3,153
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,445
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,697
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,330

Implementing Mechanism Details

Mechanism ID: 17410	Mechanism Name: USAID/Zambia Community HIV Prevention Project (Z-CHPP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 7,936,403	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,936,403	
Funding Source	Funding Amount
GHP-State	7,936,403

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	350,000
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Condom programming	200,000
Economic Strengthening	200,000

Budget Code Information

Mechanism ID: 17410			
Mechanism Name: USAID/Zambia Community HIV Prevention Project (Z-CHPP)			
Prime Partner Name: Pact			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	585,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,601,403	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	412,676
PP_PREV_DSD	Total number of people in the target population	413,396
PP_PREV_DSD	Aggregated Age/sex: <15 Male	90,227
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	114,414
PP_PREV_DSD	Aggregated Age/sex: <15 Female	89,413
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	118,622
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,481
HTC_TST_DSD	Age/sex: 10-14 Male	334
HTC_TST_DSD	Age/sex: 15-19 Male	274
HTC_TST_DSD	Age/sex: 20-24 Male	261
HTC_TST_DSD	Age/sex: 25-49 Male	680
HTC_TST_DSD	Age/sex: 50+ Male	199
HTC_TST_DSD	Age/sex: 10-14 Female	334
HTC_TST_DSD	Age/sex: 15-19 Female	291
HTC_TST_DSD	Age/sex: 20-24 Female	274
HTC_TST_DSD	Age/sex: 25-49 Female	678
HTC_TST_DSD	Age/sex: 50+ Female	200
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,525
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	44



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	36
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	36
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	89
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	25
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	43
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	38
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	37
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	88
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	26
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,100
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,100
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,094
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,187
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	8,194
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	10,287
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	18,481
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	534
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	665
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	533
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	676
HTC_TST_DSD	Test Result by Age: Positive: 1-9	194
HTC_TST_DSD	Age/sex: 1-9	1,495
HTC_TST_DSD	Service Delivery Point (Community): Index testing	1,848
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	9,240



HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	2,773
HTC_TST_DSD	Service Delivery Point (Community): Other	4,620
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,513
HTC_TST_TA	Age/sex: 10-14 Male	69
HTC_TST_TA	Age/sex: 15-19 Male	60
HTC_TST_TA	Age/sex: 20-24 Male	134
HTC_TST_TA	Age/sex: 25-49 Male	305
HTC_TST_TA	Age/sex: 50+ Male	68
HTC_TST_TA	Age/sex: 10-14 Female	161
HTC_TST_TA	Age/sex: 15-19 Female	162
HTC_TST_TA	Age/sex: 20-24 Female	134
HTC_TST_TA	Age/sex: 25-49 Female	329
HTC_TST_TA	Age/sex: 50+ Female	71
HTC_TST_TA	Sum of Age/Sex disaggregates	1,493
HTC_TST_TA	Age/sex: <1	62
HTC_TST_TA	Age/sex: 1-9	779
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	30,001
OVC_SERV_DSD	Age/Sex: 18+ Male	6,784
OVC_SERV_DSD	Age/Sex: 18+ Female	6,992
OVC_SERV_DSD	Sum of Age/Sex disaggregates	13,776
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,262
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,200
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,174
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	903
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	769



	and sex: Education Support Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	752
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	315
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	300
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	294
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	226
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	189
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	947
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	901
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	881
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	678
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	577
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	564
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	631
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	601
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	588
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	452



	and sex: Economic Strengthening Male 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	384
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	376
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	8,063
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	8,162

Implementing Mechanism Details

Mechanism ID: 17413	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17422	Mechanism Name: USAID Open Doors
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,200,000	
Funding Source	Funding Amount
GHP-State	2,200,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	1,100,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance



Key Populations: FSW	800,000
Focus Area:	Collection and use of strategic information on SWs and clients

Budget Code Information

Mechanism ID: 17422			
Mechanism Name: USAID Open Doors			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,000,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,000
KP_PREV_DSD	Total estimated number of key population in the catchment area	7,000
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300
KP_PREV_DSD	By key population type: Female sex workers (FSW)	6,700



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	300
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,700
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,989
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,176
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,412
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,053
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,348
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,229
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,760
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	11,989
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	240
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	220
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	255
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	300
HTC_TST_DSD	Service Delivery Point (Community): Other	11,989

Implementing Mechanism Details



Mechanism ID: 17425	Mechanism Name: USAID Systems for Better Health
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,590,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,590,500	
Funding Source	Funding Amount
GHP-State	6,590,500

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,650,000
Food and Nutrition: Policy, Tools, and Service Delivery	150,000
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	17425		
Mechanism Name:	USAID Systems for Better Health		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	400,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	260,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,260,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,545,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	275,000	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,500
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	735
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	765
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	520
HRH_PRE	By Graduates: Midwives	120
HRH_PRE	By Graduates: Other	400
HRH_PRE	Sum of Graduates disaggregates	520

Implementing Mechanism Details

Mechanism ID: 17439	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 900,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 900,000	
Funding Source	Funding Amount
GHP-State	900,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17439			
Mechanism Name: MEASURE Evaluation Phase IV			
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	900,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17448	Mechanism Name: Stamping Out and Preventing Gender Based Violence (STOP GBV) : Access to Justice
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Women and Law in Southern Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 370,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 370,000	
Funding Source	Funding Amount
GHP-State	370,000

Cross-Cutting Budget Attribution(s)



Gender: GBV	370,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID:	17448		
Mechanism Name:	Stamping Out and Preventing Gender Based Violence (STOP GBV) :		
Prime Partner Name:	Access to Justice		
	Women and Law in Southern Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	370,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
GEND_GBVDSD	Number of people receiving post-GBV care	10,018
GEND_GBVDSD	Age/Sex: <10 Male	272



GEND_GBV_DSD	Age/Sex: 10-14 Male	415
GEND_GBV_DSD	Age/Sex: 20-24 Male	692
GEND_GBV_DSD	Age/Sex: 25-49 Male	885
GEND_GBV_DSD	Age/Sex: 50+ Male	590
GEND_GBV_DSD	Age/Sex: <10 Female	360
GEND_GBV_DSD	Age/Sex: 10-14 Female	540
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,370
GEND_GBV_DSD	Age/Sex: 25-49 Female	2,085
GEND_GBV_DSD	Age/Sex: 50+ Female	1,415
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	1,587
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,013
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,005
GEND_GBV_DSD	Age/Sex: 15-19 Female	829
GEND_GBV_DSD	Age/Sex: 15-19 male	565

Implementing Mechanism Details

Mechanism ID: 17449	Mechanism Name: Fostering Accountability and Transparency in Zambia (FACT-Zambia)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Counterpart International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 29,673	
Applied Pipeline Amount: 70,327	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	29,673

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17449			
Mechanism Name: Fostering Accountability and Transparency in Zambia (FACT-Zambia)			
Prime Partner Name: Counterpart International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	29,673	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17477	Mechanism Name: ASM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17477			
Mechanism Name: ASM			
Prime Partner Name: American Society for Microbiology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17478	Mechanism Name: CLSI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17478			
Mechanism Name: CLSI			
Prime Partner Name: Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17479	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,145,918	
Applied Pipeline Amount: 195,082	
Total All Funding Sources and Applied Pipeline Amount: 5,341,000	
Funding Source	Funding Amount
GHP-State	5,145,918

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17479			
Mechanism Name: APHL			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	919,918	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,226,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17483	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17497	Mechanism Name: University of Maryland (SMACHT)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 6,890,326	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,890,326	
Funding Source	Funding Amount
GHP-State	6,890,326

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17497			
Mechanism Name: University of Maryland (SMACHT)			
Prime Partner Name: University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,117,078	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,723,248	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	100,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,834
PMTCT_ART_DSD	New on ART	999
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	666
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,834
PMTCT_STAT_DSD	Number of new ANC and L&D clients	12,834
PMTCT_STAT_DSD	By: Known positives at entry	910
PMTCT_STAT_DSD	By: Number of new positives identified	608
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,518
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	27
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	88
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	225



	new positives: 20-24	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	57
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	167
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	298
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	945
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	2,149
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	3,941
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	5,642
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	157
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	377
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	260
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	6
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	909
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2,045
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	3,894
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	5,829
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	157
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	33,874
PP_PREV_DSD	Total number of people in the target population	33,874



PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,693
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	10,669
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,693
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	19,819
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,913
HTC_TST_DSD	Age/sex: 10-14 Male	222
HTC_TST_DSD	Age/sex: 15-19 Male	648
HTC_TST_DSD	Age/sex: 20-24 Male	2,303
HTC_TST_DSD	Age/sex: 25-49 Male	3,071
HTC_TST_DSD	Age/sex: 50+ Male	654
HTC_TST_DSD	Age/sex: 10-14 Female	221
HTC_TST_DSD	Age/sex: 15-19 Female	1,196
HTC_TST_DSD	Age/sex: 20-24 Female	4,256
HTC_TST_DSD	Age/sex: 25-49 Female	5,575
HTC_TST_DSD	Age/sex: 50+ Female	1,199
HTC_TST_DSD	Sum of Age/Sex disaggregates	19,345
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	22
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	69
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	237
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	294
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	69
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	125
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	427
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	554
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	119
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,013
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,522



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,015
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,363
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,028
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	18,885
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,913
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	110
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	823
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	114
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,260
HTC_TST_DSD	Test Result by Age: Positive: <1	37
HTC_TST_DSD	Test Result by Age: Positive: 1-9	117
HTC_TST_DSD	Age/sex: <1	400
HTC_TST_DSD	Age/sex: 1-9	1,168
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	83
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	6,148
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,041
HTC_TST_DSD	Service Delivery Point (Facility): VCT	3,386
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,232
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,023
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	378
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	378
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	118



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	222
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	637
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	637
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	33
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	199
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	33
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	372
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	8,274
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	411
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,610



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	411
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,842
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,069
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,069
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,449
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	516
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	105
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	839
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	573
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,412
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	25
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	25
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,939
TX_CURR_DSD	Age/Sex: 15-19 Male	501
TX_CURR_DSD	Age/Sex: 15-19 Female	933
TX_CURR_DSD	Sum of age/sex disaggregates	1,434
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	798
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,731
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	801
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	8,609
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,599
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	14,340
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	15,939
TX_CURR_DSD	Age/Sex: <1	462



TX_CURR_DSD	Age/Sex: <1-9	811
TX_CURR_DSD	Age/Sex: 10-14 Male	161
TX_CURR_DSD	Age/Sex: 10-14 Female	160
TX_CURR_DSD	Age/Sex: 20-24 Male	1,758
TX_CURR_DSD	Age/Sex: 25-49 Male	2,261
TX_CURR_DSD	Age/Sex: 50+ Male	501
TX_CURR_DSD	Age/Sex: 20-24 Female	3,262
TX_CURR_DSD	Age/Sex: 25-49 Female	4,199
TX_CURR_DSD	Age/Sex: 50+ Female	930
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,362
TX_NEW_DSD	By Age/Sex: <1	31
TX_NEW_DSD	By Age/Sex: 1-9	60
TX_NEW_DSD	By Age/Sex: 10-14 Male	15
TX_NEW_DSD	By Age/Sex: 15-19 Male	38
TX_NEW_DSD	By Age/Sex: 20-24 Male	144
TX_NEW_DSD	By Age/Sex: 25-49 Male	196
TX_NEW_DSD	By Age/Sex: 50+ Male	39
TX_NEW_DSD	By Age/Sex: 10-14 Female	16
TX_NEW_DSD	By Age/Sex: 15-19 Female	73
TX_NEW_DSD	By Age/Sex: 20-24 Female	260
TX_NEW_DSD	By Age/Sex: 25-49 Female	423
TX_NEW_DSD	By Age/Sex: 50+ Female	67
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,271
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	64
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	459
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	66
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	773
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,362
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	3,679



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,687
TX_PVLS_DSD	Numerator: Indication: Routine	3,312
TX_PVLS_DSD	Numerator: Indication: Targeted	367
TX_PVLS_DSD	Denominator: Indication: Routine	3,321
TX_PVLS_DSD	Denominator: Indication: Targeted	366
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	185
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,157
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	185
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	2,152
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	185
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,159
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	185
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	2,158
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,555
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,595
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	47
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	105
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	51
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	0



TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	228
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	570
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	111
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	690
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	695
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	106
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of	51



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	228
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	570
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	690



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	695
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	122
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	819
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,491
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	122
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	815



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	127
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,491

Implementing Mechanism Details

Mechanism ID: 17499	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17500	Mechanism Name: UNZA M&E, Department of Population Studies
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17500			
Mechanism Name: UNZA M&E, Department of Population Studies			
Prime Partner Name: University of Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17502		Mechanism Name: UNC Eastern	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: University of North Carolina			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17502		
Mechanism Name:	UNC Eastern		
Prime Partner Name:	University of North Carolina		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17513	Mechanism Name: Ministry of Health
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,542,894	
---	--



Applied Pipeline Amount: 357,283	
Total All Funding Sources and Applied Pipeline Amount: 3,900,177	
Funding Source	Funding Amount
GHP-State	3,542,894

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17513			
Mechanism Name: Ministry of Health			
Prime Partner Name: Ministry of Health, Zambia			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	255,342	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	851,141	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	638,356	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	170,384	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	127,671	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17514	Mechanism Name: Jhpiego Follow-On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,647,328	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,647,328	
Funding Source	Funding Amount
GHP-State	3,647,328



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17514			
Mechanism Name: Jhpiego Follow-On			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	320,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,027,328	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	400,000	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	43,090
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	15,079
VMMC_CIRC_DSD	By Age: 15-19	10,781
VMMC_CIRC_DSD	By Age: 20-24	8,617
VMMC_CIRC_DSD	By Age: 25-29	6,468
VMMC_CIRC_DSD	By Age: 30-49	1,086
VMMC_CIRC_DSD	By Age: 50+	1,059
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	35,536
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	43,090
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	42,690
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	400

Implementing Mechanism Details

Mechanism ID: 17523	Mechanism Name: Ministry of Home Affairs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 866,710	
Applied Pipeline Amount: 53,290	
Total All Funding Sources and Applied Pipeline Amount: 920,000	
Funding Source	Funding Amount
GHP-State	866,710



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17523		
Mechanism Name:	Ministry of Home Affairs		
Prime Partner Name:	New Partner		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	421,788	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	93,731	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	281,191	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	70,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,496
HTC_TST_DSD	Age/sex: 15-19 Male	229
HTC_TST_DSD	Age/sex: 20-24 Male	916
HTC_TST_DSD	Age/sex: 25-49 Male	229



HTC_TST_DSD	Age/sex: 15-19 Female	229
HTC_TST_DSD	Age/sex: 20-24 Female	916
HTC_TST_DSD	Age/sex: 25-49 Female	229
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,748
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	114
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	114
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	18
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,748
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,748
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	5,496
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	5,496
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	342
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	342
HTC_TST_DSD	Service Delivery Point (Community): Index testing	2,748
HTC_TST_DSD	Service Delivery Point (Facility): VCT	2,748
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	48
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	48
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	34
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	34
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB	2,184



	symptoms at the last clinical visit at a HIV facility during the reporting period.	
--	--	--

Implementing Mechanism Details

Mechanism ID: 17573	Mechanism Name: Global Nursing Capacity Building Program
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17573			
Mechanism Name: Global Nursing Capacity Building Program			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17781	Mechanism Name: Health Communications Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Center for Communication Programs	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17781		
Mechanism Name:	Health Communications Collaborative (HC3)		
Prime Partner Name:	Johns Hopkins University Center for Communication Programs		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17788	Mechanism Name: USAID/South-Central Zambia Family Activity
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Development Aid from People to People Humana Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,211,118	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,211,118	
Funding Source	Funding Amount
GHP-State	6,211,118

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	354,969
Economic Strengthening	1,262,113
Education	1,498,759
Human Resources for Health	828,262
Water	300,000

Budget Code Information

Mechanism ID: 17788



Mechanism Name:	USAID/South-Central Zambia Family Activity		
Prime Partner Name:	Development Aid from People to People Humana Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,774,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	4,437,118	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,540
HTC_TST_DSD	Age/sex: 10-14 Male	81
HTC_TST_DSD	Age/sex: 15-19 Male	135
HTC_TST_DSD	Age/sex: 10-14 Female	81
HTC_TST_DSD	Age/sex: 15-19 Female	135
HTC_TST_DSD	Sum of Age/Sex disaggregates	432
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	4
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	647
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	502
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	501



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	356
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,148
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	858
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,006
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	108
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	129,000
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	6,966
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,903
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	4,644
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	968
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Education Support Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	839
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	18,705
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	8,385
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	839
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	18,705
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	8,385
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	839
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	18,705
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	8,385
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	839
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	18,705
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	8,385
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	810
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	18,068
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	8,100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Economic Strengthening Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	810
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	18,068
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	8,100
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	5,160
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	23,865
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	23,865
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	23,053
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	64,500
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	64,500
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	7,740



	and sex: Education Support Female 1-9	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	23,865
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	23,865
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	23,053
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	0

Implementing Mechanism Details

Mechanism ID: 17807	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17833	Mechanism Name: Project SOAR
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17833			
Mechanism Name: Project SOAR			
Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17873	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17891	Mechanism Name: ASLM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 302,639	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 302,639	
Funding Source	Funding Amount
GHP-State	302,639



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17891			
Mechanism Name: ASLM			
Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	302,639	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17897	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17927	Mechanism Name: Safe Motherhood 360+
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Churches Health Association of Zambia	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Condom programming	150,000
--------------------	---------

Budget Code Information

Mechanism ID:	17927		
Mechanism Name:	Safe Motherhood 360+		
Prime Partner Name:	Churches Health Association of Zambia		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	50,000



PP_PREV_DSD	Total number of people in the target population	1,835,357
PP_PREV_DSD	Aggregated Age/sex: <15 Male	4,943
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	19,240
PP_PREV_DSD	Aggregated Age/sex: <15 Female	4,893
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	20,924

Implementing Mechanism Details

Mechanism ID: 18159	Mechanism Name: Global Health Supply Chain Program
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 107,515,847	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 107,515,847	
Funding Source	Funding Amount
GHP-State	107,515,847

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	1,245,000
Construction	1,116,000
Condom procurement	1,793,324

Budget Code Information

Mechanism ID:	18159
Mechanism Name:	Global Health Supply Chain Program



Prime Partner Name: Global Health Supply Chain Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	6,310,024	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,113,534	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,524,865	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	3,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	5,593,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,793,324	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	46,081,272	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	37,645,094	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	4,454,134	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	4,026,104
INVS_COMD	Number of HIV ARVs purchased	4,026,104
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	240,365

Implementing Mechanism Details

Mechanism ID: 18160	Mechanism Name: AIDSFree ZAMBIA
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 5,297,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,297,500	
Funding Source	Funding Amount
GHP-State	5,297,500

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18160
Mechanism Name: AIDSFree ZAMBIA



Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,297,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,400

Implementing Mechanism Details

Mechanism ID: 18161	Mechanism Name: USAID GHSC-RTK
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Remote Medical International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18161			
Mechanism Name: USAID GHSC-RTK			
Prime Partner Name: Remote Medical International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	51,000
INVS_COMD	Number of HIV Test Kits purchased	51,000
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	5,229,941

Implementing Mechanism Details

Mechanism ID: 18251	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18259	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18263	Mechanism Name: Cash Plus Care
----------------------------	---------------------------------------

Approved



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: UNICEF	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18263			
Mechanism Name: Cash Plus Care			
Prime Partner Name: UNICEF			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18278	TBD: Yes
----------------------------	-----------------



REDACTED

Implementing Mechanism Details

Mechanism ID: 18297	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18304	Mechanism Name: EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 4,220,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,220,000	
Funding Source	Funding Amount
GHP-State	4,220,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18304		
Mechanism Name:	EQUIP		
Prime Partner Name:	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,720,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18322	Mechanism Name: Quality Improvement and Capacity for Impact Project (QICIP)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18322		
Mechanism Name:	Quality Improvement and Capacity for Impact Project (QICIP)		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18323	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18324	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18325	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18327	TBD: Yes
----------------------------	-----------------



REDACTED

Implementing Mechanism Details

Mechanism ID: 18332	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18335	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18342	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18344	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18345	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18346	Mechanism Name: U.S. Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 307,052	
Applied Pipeline Amount: 15,154	
Total All Funding Sources and Applied Pipeline Amount: 322,206	
Funding Source	Funding Amount
GHP-State	307,052

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18346		
Mechanism Name:	U.S. Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	52,563	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	63,030	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	191,459	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18457	TBD: Yes
REDACTED	

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		610,000		0	610,000	610,000
ICASS		1,200,000		0	1,200,000	1,200,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		420,000		0	420,000	420,000
Non-ICASS Administrative Costs		814,931		0	814,931	814,931
Staff Program Travel		550,000		0	550,000	550,000
USG Staff Salaries and Benefits - Internationally Recruited		2,800,079		0	2,800,079	2,800,079
USG Staff		2,324,023		0	2,324,023	2,324,023



Salaries and Benefits - Locally Recruited						
Total	0	8,719,033	0	0	8,719,033	8,719,033

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		50,000		0	50,000	50,000
ICASS		80,000		20,000	80,000	100,000
Indirect Costs		20,000		20,000	20,000	40,000
Management Meetings/Professional Development		70,000		50,000	70,000	120,000
Non-ICASS Administrative Costs		10,000		10,000	10,000	20,000
Staff Program Travel		220,000		80,000	220,000	300,000
USG Staff Salaries and Benefits - Locally Recruited		260,000		110,000	260,000	370,000



Total	0	710,000	0	290,000	710,000	1,000,000
--------------	----------	----------------	----------	----------------	----------------	------------------

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		376,440		0	376,440	376,440
Computers/IT Services		460,906		0	460,906	460,906
ICASS		1,720,532		0	1,720,532	1,720,532
Institutional Contractors		1,326,927		0	1,326,927	1,326,927
Management Meetings/Professional Development		50,000		0	50,000	50,000
Non-ICASS Administrative Costs		1,054,496		0	1,054,496	1,054,496
Staff Program Travel		1,932,288		0	1,932,288	1,932,288
USG Renovation		150,000		0	150,000	150,000
USG Staff Salaries and Benefits -	2,412,531			0	2,412,531	2,412,531



Internationally Recruited						
USG Staff Salaries and Benefits - Locally Recruited		3,012,284		0	3,012,284	3,012,284
Total	2,412,531	10,083,873	0	0	12,496,404	12,496,404

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		8,712		1,288	8,712	10,000
ICASS		349,572		51,683	349,572	401,255
Indirect Costs		258,611		61,152	258,611	319,763
Management Meetings/Professional Development		125,980		18,626	125,980	144,606
Non-ICASS Administrative Costs		422,160		39,499	422,160	461,659
Staff Program Travel		35,410		5,235	35,410	40,645
USG Staff Salaries and		385,460		149,504	385,460	534,964



Benefits - Locally Recruited						
Total	0	1,585,905	0	326,987	1,585,905	1,912,892

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Management Meetings/Profes sional Development		18,106		894	18,106	19,000
Non-ICASS Administrative Costs		280,528		13,845	280,528	294,373
Non-ICASS Motor Vehicles		85,767		4,233	85,767	90,000
Peace Corps Volunteer Costs		2,451,834		121,006	2,451,834	2,572,840
Staff Program Travel		130,422		6,437	130,422	136,859
USG Staff Salaries and Benefits - Locally Recruited		1,125,790		55,562	1,125,790	1,181,352
Total	0	4,092,447	0	201,977	4,092,447	4,294,424

Approved

